beta

AGN

Allergan plc

Agn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

10-30-2018 07-26-2018 04-30-2018 02-06-2018 11-01-2017 08-03-2017 05-09-2017
Actual EPS 4.25 4.42 3.74 4.86 4.15 4.02 3.35
Consensus EPS 4.01 4.13 3.36 4.75 4.06 3.95 3.32
Estimated EPS 4.01 4.13 3.36 4.75 4.06 3.95 3.32
Number of Estimates 19 20 23 18 19 17 18
EPS Surprise $0.24 $0.29 $0.38 $0.11 $0.09 $0.07 $0.03

Stats

Summary

Allergan PLC is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and OTC pharmaceutical products.

Market Cap: 62.2 Billion

Primary Exchange: New York Stock Exchange

Website: http://www.allergan.com

Shares Outstanding: 333 Million

Float: 330 Million

Dividend: 2.8 (1.5%)

Beta: 1.234322

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 11 Million

Ethical Flags

Animal testing

Longest drawdown: 848 trading days

From: 2015-07-28 To: 2018-12-14

Lowest Point:

Mylan launches generic version Shire's Lialda; shares up 1%

via: SeekingAlpha at 2018-12-17 11:17:30:000

Mylan N.V. ( MYL +0.9% ) announces the U.S. launch of its generic version of Shire plc's ( SHPG -2.1% ) ulcerative colitis med Lialda (mesalamine) Delayed-Release Tablets. More news on: Mylan Inc, Shire PLC, Allergan plc, Healthcare stocks news, Stocks on the move, Read more … ... read more...

Teva up 1% premarket on positive fremanezumab data

via: SeekingAlpha at 2018-12-17 08:38:40:000

Teva Pharmaceutical Industries (NYSE: TEVA ) is up 1% premarket on modest volume in response to its announcement of positive results from a Phase 3 clinical trial, FOCUS , evaluating fremanezumab in adults with chronic or episodic migraine. More news on: Teva Pharmaceutical … read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

Senate Dems introduce bill to block "excessive" increases in drug prices

via: SeekingAlpha at 2018-12-13 14:24:06:000

Four democratic senators, Richard Blumenthal (D-CT), Kamala Harris (D-CA), Amy Klobuchar (D-MN) and Jeff Merkley (D-OR), have introduced a bill aimed at blocking drug price hikes. Specifically, it will allow the Department of Health and Human Services to prohibit price increases that it co… read more...

Aclaris Therapeutics: A Promising Dermatology Buy In 2018

via: SeekingAlpha at 2018-12-11 13:44:13:000

Headquartered in Pennsylvania, Aclaris Therapeutics ( ACRS ) is a biopharmaceutical company focused on developing novel therapies targeting various skin and hair conditions. In the third quarter, Aclaris Therapeutics missed the consensus revenue estimate by $0.12 million but beat the GAAP … read more...

Allergan plc (AGN) CEO Brenton Saunders Presents at Citi Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-12-06 15:24:04:000

Allergan plc (AGN) Citi Global Healthcare Conference (Transcript) December 6, 2018, 11:00 AM ET Executives Brenton Saunders - Chairman, President and Chief Executive Officer Analysts Liav Abraham - Citigroup Presentation Liav Abraham Thank you, everyone. My name is Li… read more...

Allergan plc (AGN) CEO Brenton Saunders Presents at Citi Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-12-06 15:24:04:000

Allergan plc (AGN) Citi Global Healthcare Conference (Transcript) December 6, 2018, 11:00 AM ET Executives Brenton Saunders - Chairman, President and Chief Executive Officer Analysts Liav Abraham - Citigroup Presentation Liav Abraham Thank you, everyone. My name is Li… read more...

Allergan plc (AGN) CEO Brenton Saunders Presents at Citi Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-12-06 15:24:04:000

Allergan plc (AGN) Citi Global Healthcare Conference (Transcript) December 6, 2018, 11:00 AM ET Executives Brenton Saunders - Chairman, President and Chief Executive Officer Analysts Liav Abraham - Citigroup Presentation Liav Abraham Thank you, everyone. My name is Li… read more...

THW: Global Healthcare Fund With 10%+ Yield

via: SeekingAlpha at 2018-12-06 13:45:07:000

Tekla World Healthcare Fund ( THW ) is quite similar to another fund I just recently covered , Tekla Healthcare Opportunities Fund ( THQ ). Both funds focused on the healthcare sector. Actually, the four funds Tekla offers all cover healthcare related sectors. I believe THW is at a level offe… read more...

THW: Global Healthcare Fund With 10%+ Yield

via: SeekingAlpha at 2018-12-06 13:45:07:000

Tekla World Healthcare Fund ( THW ) is quite similar to another fund I just recently covered , Tekla Healthcare Opportunities Fund ( THQ ). Both funds focused on the healthcare sector. Actually, the four funds Tekla offers all cover healthcare related sectors. I believe THW is at a level offe… read more...

THW: Global Healthcare Fund With 10%+ Yield

via: SeekingAlpha at 2018-12-06 13:45:07:000

Tekla World Healthcare Fund ( THW ) is quite similar to another fund I just recently covered , Tekla Healthcare Opportunities Fund ( THQ ). Both funds focused on the healthcare sector. Actually, the four funds Tekla offers all cover healthcare related sectors. I believe THW is at a level offe… read more...

Biohaven Pharma up 17% on positive data on migraine med Zydis

via: SeekingAlpha at 2018-12-03 12:05:58:000

Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...

Biohaven Pharma up 17% on positive data on migraine med Zydis

via: SeekingAlpha at 2018-12-03 12:05:58:000

Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...

Biohaven Pharma up 17% on positive data on migraine med Zydis

via: SeekingAlpha at 2018-12-03 12:05:58:000

Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...

UBS Global Wealth Management to include environmental scores on its funds in 2019

via: CNBC at 2018-12-03 07:20:00:000

No summary available. read more...

UBS Global Wealth Management to include environmental scores on its funds in 2019

via: CNBC at 2018-12-03 07:20:00:000

No summary available. read more...

UBS Global Wealth Management to include environmental scores on its funds in 2019

via: CNBC at 2018-12-03 07:20:00:000

No summary available. read more...

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

via: SeekingAlpha at 2018-11-30 11:58:26:000

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. … read more...

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

via: SeekingAlpha at 2018-11-30 11:58:26:000

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. … read more...

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

via: SeekingAlpha at 2018-11-30 11:58:26:000

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. … read more...

FDA signs off on Editas Medicine's IND for gene-editing candidate for LCA10

via: SeekingAlpha at 2018-11-30 07:47:02:000

The FDA has approved Editas Medicine's (NASDAQ: EDIT ) Investigational New Drug (IND) application seeking signoff for clinical studies evaluating genome-editing candidate EDIT-101 for the potential treatment of Leber Congenital Amaurosis type 10 (LCA10), a group of inherited retinal disord… read more...

FDA signs off on Editas Medicine's IND for gene-editing candidate for LCA10

via: SeekingAlpha at 2018-11-30 07:47:02:000

The FDA has approved Editas Medicine's (NASDAQ: EDIT ) Investigational New Drug (IND) application seeking signoff for clinical studies evaluating genome-editing candidate EDIT-101 for the potential treatment of Leber Congenital Amaurosis type 10 (LCA10), a group of inherited retinal disord… read more...

FDA signs off on Editas Medicine's IND for gene-editing candidate for LCA10

via: SeekingAlpha at 2018-11-30 07:47:02:000

The FDA has approved Editas Medicine's (NASDAQ: EDIT ) Investigational New Drug (IND) application seeking signoff for clinical studies evaluating genome-editing candidate EDIT-101 for the potential treatment of Leber Congenital Amaurosis type 10 (LCA10), a group of inherited retinal disord… read more...

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-28 03:24:10:000

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitzs 13F portfolio on a quarterly basis. It is based on Weitzs regulatory 13F Form filed on 11/13/2018. Please visit our Tracking Wallace Weitzs Weitz Investment Man… read more...

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-28 03:24:10:000

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitzs 13F portfolio on a quarterly basis. It is based on Weitzs regulatory 13F Form filed on 11/13/2018. Please visit our Tracking Wallace Weitzs Weitz Investment Man… read more...

Allergan Makes New Appointments to Finance Leadership Team

via: PR Newswire at 2018-11-26 07:30:00:000

DUBLIN , Nov. 26, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, and Manisha Narasimhan , Ph… read more...

Allergan Makes New Appointments to Finance Leadership Team

via: PR Newswire at 2018-11-26 07:30:00:000

DUBLIN , Nov. 26, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, and Manisha Narasimhan , Ph… read more...

Viking Therapeutics Won't Live Up To The Hype

via: SeekingAlpha at 2018-11-26 05:00:00:000

NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...

Viking Therapeutics Won't Live Up To The Hype

via: SeekingAlpha at 2018-11-26 05:00:00:000

NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...

What Is Bausch Health Companies Stock Worth?

via: SeekingAlpha at 2018-11-25 11:47:47:000

After shares of Bausch Health Companies ( BHC ) touched close to the $28 level on three occasions since June, the stock continues to spend most of its time in the $22-$24 level. And yet in the third quarter, the company demonstrated that its turnaround is firmly playing out. Chances are good… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-24 12:07:31:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins 13F portfolio on a quarterly basis. It is based on Hawkins regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Mason Hawkins Southeastern Asset Mana… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-24 04:56:54:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins' 13F portfolio on a quarterly basis. It is based on Robbins' regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Larry Robbins' Glenview Capital Management Portfolio artic… read more...

ClearBridge Value Equity Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-23 11:15:00:000

Read more … read more...

Hedge funds are in a 'vicious downward cycle' as their favorite stocks badly trail market

via: CNBC at 2018-11-21 13:15:00:000

No summary available. read more...

Hedge funds are in a 'vicious downward cycle' as their favorite stocks badly trail market

via: CNBC at 2018-11-21 13:15:00:000

No summary available. read more...

Tracking David Tepper's Appaloosa Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-21 08:22:19:000

This article is part of a series that provides an ongoing analysis of the changes made to David Teppers 13F portfolio on a quarterly basis. It is based on Appaloosa Managements regulatory 13F Form filed on 11/14/2018. Please visit our Tracking David Teppers Appaloosa… read more...

Tracking David Tepper's Appaloosa Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-21 08:22:19:000

This article is part of a series that provides an ongoing analysis of the changes made to David Teppers 13F portfolio on a quarterly basis. It is based on Appaloosa Managements regulatory 13F Form filed on 11/14/2018. Please visit our Tracking David Teppers Appaloosa… read more...

Allergan to Present at the 2018 Citi Global Healthcare Conference

via: PR Newswire at 2018-11-20 08:00:00:000

DUBLIN , Nov. 20, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Citi Global Healthcare Conference in New York City . The presentation will… read more...

Allergan Announces FDA Acceptance of Supplemental New Drug Application for AVYCAZ® (ceftazidime and avibactam)

via: PR Newswire at 2018-11-20 07:30:00:000

DUBLIN , Nov. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam),seeking to expand the l… read more...

Tracking John Paulson's Paulson & Company Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-20 07:19:53:000

This article is part of a series that provides an ongoing analysis of the changes made to John Paulsons 13F stock portfolio on a quarterly basis. It is based on Paulsons regulatory 13F Form filed on 11/14/2018. Please visit our Tracking John Paulsons Paulson & Co… read more...

NGM Biopharmaceuticals And NASH: Making Progress

via: SeekingAlpha at 2018-11-19 15:29:24:000

Any man or institution that tries to rob me of my dignity will lose - Nelson Mandela Introduction The once dormant clinical research and development of therapies for the non-viral liver disease, NASH, is now characterized by intense competition with over 30 innovative drug candidate… read more...

Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update

via: SeekingAlpha at 2018-11-14 17:26:08:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 11/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update

via: SeekingAlpha at 2018-11-14 17:26:08:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 11/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update

via: SeekingAlpha at 2018-11-14 17:26:08:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 11/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

ClearBridge International Value Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-14 08:33:00:000

Read more … read more...

ClearBridge International Value Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-14 08:33:00:000

Read more … read more...

ClearBridge International Value Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-14 08:33:00:000

Read more … read more...

Pfizer loses Lyrica patent fight

via: SeekingAlpha at 2018-11-14 06:35:08:000

Britain's Supreme Court has ruled against Pfizer (NYSE: PFE ) in a the final round of a long-running patent battle involving its $5B-a-year pain drug Lyrica. More news on: Pfizer Inc., Allergan plc, Mylan Inc, Healthcare stocks news, Read more … read more...

Pfizer loses Lyrica patent fight

via: SeekingAlpha at 2018-11-14 06:35:08:000

Britain's Supreme Court has ruled against Pfizer (NYSE: PFE ) in a the final round of a long-running patent battle involving its $5B-a-year pain drug Lyrica. More news on: Pfizer Inc., Allergan plc, Mylan Inc, Healthcare stocks news, Read more … read more...

Pfizer loses Lyrica patent fight

via: SeekingAlpha at 2018-11-14 06:35:08:000

Britain's Supreme Court has ruled against Pfizer (NYSE: PFE ) in a the final round of a long-running patent battle involving its $5B-a-year pain drug Lyrica. More news on: Pfizer Inc., Allergan plc, Mylan Inc, Healthcare stocks news, Read more … read more...

Alder Biopharmaceuticals: Pure Play Migraine Prevention Treatment In A Crowded Space

via: SeekingAlpha at 2018-11-13 16:09:20:000

The Migraine prevention market is estimated to be around $8 billion . Based on the number of migraineurs and the cost per treatment, that might be low. Three new preventative treatments, Lilly's Emgality, Amgen/Novartis Aimovig, and Teva's Ajovy, have been approved in 2018. These are all… read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

ClearBridge Aggressive Growth Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-13 05:35:00:000

Read more … read more...

RedHill And Talicia: I Say Yes

via: SeekingAlpha at 2018-11-09 14:11:58:000

Author's note: I am grateful to COO, Gilead Raday and management for granting me a call interview for this article. The therapeutic battle for clinical excellence starts in the mind of a visionary who thinks outside the box to develop a paradigm changing pharmacological approach to disease… read more...

RedHill And Talicia: I Say Yes

via: SeekingAlpha at 2018-11-09 14:11:58:000

Author's note: I am grateful to COO, Gilead Raday and management for granting me a call interview for this article. The therapeutic battle for clinical excellence starts in the mind of a visionary who thinks outside the box to develop a paradigm changing pharmacological approach to disease… read more...

RedHill And Talicia: I Say Yes

via: SeekingAlpha at 2018-11-09 14:11:58:000

Author's note: I am grateful to COO, Gilead Raday and management for granting me a call interview for this article. The therapeutic battle for clinical excellence starts in the mind of a visionary who thinks outside the box to develop a paradigm changing pharmacological approach to disease… read more...

RedHill And Talicia: I Say Yes

via: SeekingAlpha at 2018-11-09 14:11:58:000

Author's note: I am grateful to COO, Gilead Raday and management for granting me a call interview for this article. The therapeutic battle for clinical excellence starts in the mind of a visionary who thinks outside the box to develop a paradigm changing pharmacological approach to disease… read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

The midterm election could decide the fate of these three health-care groups

via: CNBC at 2018-11-06 16:54:00:000

No summary available. read more...

The midterm election could decide the fate of these three health-care groups

via: CNBC at 2018-11-06 16:54:00:000

No summary available. read more...

The midterm election could decide the fate of these three health-care groups

via: CNBC at 2018-11-06 16:54:00:000

No summary available. read more...

Allergan to Present at Credit Suisse 27th Annual Healthcare Conference

via: PR Newswire at 2018-11-05 08:00:00:000

DUBLIN , Nov. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Credit Suisse 27 th Annual Health Care Conference in Scottsdale, Arizona . The presentation will beg… read more...

Looking Beyond The Election (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-04 06:30:58:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Stocks To Watch: Looking Beyond The Election

via: SeekingAlpha at 2018-11-03 09:26:43:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Yep, there is an election next week that's going to steal some headlines, but inves… read more...

Economy Is Cooling - Cramer's Mad Money (11/1/18)

via: SeekingAlpha at 2018-11-02 07:47:15:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , November 1. President's softening stance on China and Fed not raising rates are the two events the market wants. That's what happened on Thursday when Trump tweeted China and the U.S. had their … read more...

Drug stocks are 'no longer' reliable safety nets for investors: Cramer

via: CNBC at 2018-11-01 18:27:00:000

No summary available. read more...

FDA OKs genetic test to inform on drug metabolism

via: SeekingAlpha at 2018-11-01 09:33:04:000

The FDA approves a consumer-targeted molecular diagnostic test from privately held 23andme , the Personal Genome Service Pharmacogenetic Reports, that detects 33 variants for multiple genes from a saliva sample. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnolog… read more...

The Biotech Bumps

via: SeekingAlpha at 2018-11-01 08:00:45:000

We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October… read more...

Bulls Pin Hopes On Market Rebound (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-10-31 07:49:00:000

Today's top stories: Bulls pin hopes on market rebound; Chinese equities tracking gains on Wall Street; and Samsung posts record profit. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking… read more...

Wall Street Breakfast: Rough October Ends On Upbeat Note

via: SeekingAlpha at 2018-10-31 06:59:09:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). European stocks advanced overnight, tracking a rebound across Asia, as U.S. futures extended gains on the last day… read more...

Pharma's support of Trump's drug pricing plan is fraying heading into midterms

via: CNBC at 2018-10-30 13:41:00:000

No summary available. read more...

Allergan Plc (AGN) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-30 12:40:48:000

Allergan Plc (AGN) Q3 2018 Earnings Call October 30, 2018 8:30 am ET Executives Daphne Karydas - Allergan Plc Brenton L. Saunders - Allergan Plc William J. Meury - Allergan Plc C. David Nicholson - Allergan Plc Matthew M. Walsh - Allergan Plc Analysts Liav Abraham - Cit… read more...

Allergan plc 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-30 10:47:37:000

The following slide deck was published by Allergan plc in conjunction with their 2018 Q3 earnings Read more … read more...

Allergan Q3 revenues down 3%; non-GAAP EPS up 2%; raises revenue and Non-GAAP EPS guidance

via: SeekingAlpha at 2018-10-30 07:09:29:000

Allergan ( AGN ) Q3 results: Revenues: $3,911.4M (-3.0%); US Specialized Therapeutics: $1,706.2M (-1.1%); US General Medicine: $1,381.3M (-7.8%); International: $821.6M (+1.7%). More news on: Allergan plc, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Allergan beats by $0.21, beats on revenue

via: SeekingAlpha at 2018-10-30 06:33:20:000

Allergan (NYSE: AGN ): Q3 Non-GAAP EPS of $4.25 beats by $0.21 ; GAAP EPS of -$0.11 beats by $0.39 . More news on: Allergan plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Allergan Reports Third Quarter 2018 Results Including GAAP Net Revenues of $3.9 Billion

via: PR Newswire at 2018-10-30 06:30:00:000

DUBLIN , Oct. 30, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its third quarter 2018 performance. Total third quarter 2018 GAAP net revenues were $3.91 billion , a 3.0 percent decrease from the prior year quarter. THIRD QUARTER 2018 Executive Commentary … read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-10-29 17:30:46:000

ACCO , AER , AET , AGCO , AGN , AMRC , AMT , AN , AOS , ARII , ARNC , ARRY , AWI , BHGE , BKI , BP , BPMC , BTU , CEQP , CIGI , CMCO , CMI , CNX , CNXM , CTSH , CVLT , EAT , ECL , ERJ , ETN , EXP , FCAU , FDP , FIS , FLIR , FLOW , FMS , FUN , GE , GPN… read more...

Weitz Value Fund Q3 2018 Quarterly Commentary

via: SeekingAlpha at 2018-10-29 13:00:00:000

Read more … read more...

Most Important Earnings To Watch This Week

via: SeekingAlpha at 2018-10-29 12:13:01:000

We're smack dab in the middle of earnings season right now, and below is a list of the 40 largest companies set to report Q3 numbers this week. For each stock, we include a number of key data points that you won't find in most earnings calendars. Data points like historical earnings and revenu… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector

via: SeekingAlpha at 2018-10-27 08:44:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are being put to the rest with major indexes now down sharply on the year… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Allergan Declares Fourth Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share

via: PR Newswire at 2018-10-26 07:30:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the fourth quarter of 2018. The dividend will be paid on December 14, 2018 to shareholders of record at the clo… read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

CoolSculpting® And Kristin Davis Partner To Overcome Denim Denial Blues

via: PR Newswire at 2018-10-23 07:30:00:000

DUBLIN , Oct.23, 2018 /PRNewswire/ --Actress for the Emmy- and Golden Globe-winning series "Sex and the City," philanthropist and mom, Kristin Davis , is partnering with CoolSculpting the FDA-cleared non-surgical, clinically proven treatment that eliminates stu… read more...

Achaogen's Zemdri: Blockbuster Potential For A Pittance

via: SeekingAlpha at 2018-10-23 05:00:00:000

Introduction Achaogen ( AKAO ) is a commercial-stage drug developer based in the South San Francisco business park. Currently trading around $4/share, the company is valued at roughly $180m Mcap. The company had $100.5 million in cash, cash equivalents and short-term investments at 6/30/18 a… read more...

Allergan and The Allergan Foundation Support U.S. Veterans With "Heroes MAKE America" Sponsorship

via: PR Newswire at 2018-10-22 10:01:00:000

WACO, Texas , Oct. 22, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that The Allergan Foundation has awarded a $125,000 grant to support "Heroes MAKE America," a career program for veteran candidates in the United States … read more...

Allergan to Showcase Continued Eye Care Innovation with New Data on Investigational Medicines at the American Academy of Ophthalmology Annual Meeting

via: PR Newswire at 2018-10-19 07:30:00:000

DUBLIN , Oct. 19, 2018 /PRNewswire/ --Allergan plc, (NYSE: AGN) a leading global pharmaceutical company with a nearly 70-year heritage in ophthalmology, will present new data at the Annual Meeting of the American College of Ophthalmology (AAO) to be held in Chicago, Illinois . The … read more...

Allergan to Showcase Continued Eye Care Innovation with New Data on Investigational Medicines at the American Academy of Ophthalmology Annual Meeting

via: PR Newswire at 2018-10-19 07:30:00:000

DUBLIN , Oct. 19, 2018 /PRNewswire/ --Allergan plc, (NYSE: AGN) a leading global pharmaceutical company with a nearly 70-year heritage in ophthalmology, will present new data at the Annual Meeting of the American College of Ophthalmology (AAO) to be held in Chicago, Illinois . The … read more...

Allergan to Showcase Continued Eye Care Innovation with New Data on Investigational Medicines at the American Academy of Ophthalmology Annual Meeting

via: PR Newswire at 2018-10-19 07:30:00:000

DUBLIN , Oct. 19, 2018 /PRNewswire/ --Allergan plc, (NYSE: AGN) a leading global pharmaceutical company with a nearly 70-year heritage in ophthalmology, will present new data at the Annual Meeting of the American College of Ophthalmology (AAO) to be held in Chicago, Illinois . The … read more...

Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

via: PR Newswire at 2018-10-17 07:30:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine. The first study (UBR-MD-04) evaluated the long-term safety and tolerability of ubrogepant (50 m… read more...

Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

via: PR Newswire at 2018-10-17 07:30:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine. The first study (UBR-MD-04) evaluated the long-term safety and tolerability of ubrogepant (50 m… read more...

FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

via: PR Newswire at 2018-10-16 09:00:00:000

DUBLINand SAN FRANCISCO , Oct. 16, 2018 /PRNewswire/ --Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that the… read more...

Aclaris acquires rosacea cream from Allergan for $65M

via: SeekingAlpha at 2018-10-15 16:10:40:000

Aclaris Therapeutics (NASDAQ: ACRS ) has agreed to acquire global rights to Allergan's (NYSE: AGN ) RHOFADE (oxymetazoline hydrochloride) cream 1%, indicated for the topical treatment of facial redness associated with rosacea in adults. More news on: Aclaris Therapeutics, Allergan plc, H… read more...

FDA issues new guidance aimed at more efficient drug development

via: SeekingAlpha at 2018-10-15 13:49:33:000

The FDA has issued two guidance documents that it says should help make the drug development process more efficient. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, … read more...

Healthcare 16-24% Target Net Gains Pace WallStars For October

via: SeekingAlpha at 2018-10-15 09:57:51:000

Actionable Conclusions (1-10): Analysts Projected 16.2% To 23.9% Net Gains For Top 10 Healthcare WallStars By October 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker one-year target prices (… read more...

Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix

via: PR Newswire at 2018-10-11 16:15:00:000

DUBLIN , Oct. 11, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14 . The mee… read more...

Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix

via: PR Newswire at 2018-10-11 16:15:00:000

DUBLIN , Oct. 11, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14 . The mee… read more...

Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix

via: PR Newswire at 2018-10-11 16:15:00:000

DUBLIN , Oct. 11, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14 . The mee… read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

VistaGen: Expensive At 12x Its Book Value Per Share

via: SeekingAlpha at 2018-10-09 09:38:38:000

After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote… read more...

VistaGen: Expensive At 12x Its Book Value Per Share

via: SeekingAlpha at 2018-10-09 09:38:38:000

After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-09 08:14:33:000

Allergan (NYSE: AGN ) initiated with Buy rating and $259 (36% upside) at Guggenheim. More news on: Allergan plc, Bristol-Myers Squibb Company, Merck & Co Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-09 08:14:33:000

Allergan (NYSE: AGN ) initiated with Buy rating and $259 (36% upside) at Guggenheim. More news on: Allergan plc, Bristol-Myers Squibb Company, Merck & Co Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Why Peter Thiel is backing a tiny start-up waging war against the global superbug crisis

via: CNBC at 2018-10-09 06:17:00:000

No summary available. read more...

Why Peter Thiel is backing a tiny start-up waging war against the global superbug crisis

via: CNBC at 2018-10-09 06:17:00:000

No summary available. read more...

Allergan Presents New Research at the American College of Gastroenterology Annual Scientific Meeting (ACG 2018)

via: PR Newswire at 2018-10-08 08:00:00:000

DUBLIN , Oct. 8, 2018 /PRNewswire/ --Allergan plc(NYSE: AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG), from October 5-10, 2018… read more...

Expected Value Investing:  The Case Against Galmed

via: SeekingAlpha at 2018-10-05 12:20:00:000

In June, Galmed (NASDAQ: GLMD ) announced data from its Phase 2b trial evaluating its lead drug candidate Aramchol's ability to reduce liver fat in patients with NASH fibrosis . Though the drug failed its primary endpoint, it did demonstrate a moderate ability to reduce liver fat, improve … read more...

Expected Value Investing:  The Case Against Galmed

via: SeekingAlpha at 2018-10-05 12:20:00:000

In June, Galmed (NASDAQ: GLMD ) announced data from its Phase 2b trial evaluating its lead drug candidate Aramchol's ability to reduce liver fat in patients with NASH fibrosis . Though the drug failed its primary endpoint, it did demonstrate a moderate ability to reduce liver fat, improve … read more...

Expected Value Investing:  The Case Against Galmed

via: SeekingAlpha at 2018-10-05 12:20:00:000

In June, Galmed (NASDAQ: GLMD ) announced data from its Phase 2b trial evaluating its lead drug candidate Aramchol's ability to reduce liver fat in patients with NASH fibrosis . Though the drug failed its primary endpoint, it did demonstrate a moderate ability to reduce liver fat, improve … read more...

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

via: PR Newswire at 2018-10-05 07:30:00:000

DUBLIN , Oct. 5, 2018 /PRNewswire/ --Allergan plc(NYSE: AGN) today announced the initiation of two global clinical research programs for brazikumab, an investigational drug being studied for inflammatory bowel disease (IBD). INTREPID (Crohn's disease) and EXPEDITION (ulcerativ… read more...

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

via: PR Newswire at 2018-10-05 07:30:00:000

DUBLIN , Oct. 5, 2018 /PRNewswire/ --Allergan plc(NYSE: AGN) today announced the initiation of two global clinical research programs for brazikumab, an investigational drug being studied for inflammatory bowel disease (IBD). INTREPID (Crohn's disease) and EXPEDITION (ulcerativ… read more...

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

via: PR Newswire at 2018-10-05 07:30:00:000

DUBLIN , Oct. 5, 2018 /PRNewswire/ --Allergan plc(NYSE: AGN) today announced the initiation of two global clinical research programs for brazikumab, an investigational drug being studied for inflammatory bowel disease (IBD). INTREPID (Crohn's disease) and EXPEDITION (ulcerativ… read more...

Cramer reveals the 10 'telltale signs' that could prolong the sell-off

via: CNBC at 2018-10-04 18:13:00:000

No summary available. read more...

Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®

via: PR Newswire at 2018-10-04 07:30:00:000

DUBLIN , Oct. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting treatment received FDA clearance to treat the submandibular area. In addition, the FDA clearance was expanded to include patients with a BMI of up to 46.2 when treating the submen… read more...

Allergan And Cenicriviroc In NASH Fibrosis: Revisiting FDA Guidelines For Conditional Approval

via: SeekingAlpha at 2018-10-03 10:28:07:000

To be free is not merely to cast off one's chains, but to live in a way that respects and enhances the freedom of others. Nelson Mandela Investment Thesis Allergan PLC ( AGN ) is a large market cap ($65B) biopharmaceutical company with a pipeline of innovative and generic the… read more...

Health care just posted its best quarter in 5 years, but there's still value to be found says trader

via: CNBC at 2018-10-03 08:29:00:000

No summary available. read more...

Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers

via: PR Newswire at 2018-10-03 07:45:00:000

DUBLIN , Oct. 3, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) announced today the launch of a new JUVDERM advertising campaign created to empower the next generation of consumers to "JUVDERM IT." JUVDERM IT marks the first new advertising ca… read more...

NASH players under pressure following Liver Meeting abstract drop

via: SeekingAlpha at 2018-10-02 12:50:37:000

Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals… read more...

FDA issues new draft guidance aimed at speedier generic approvals

via: SeekingAlpha at 2018-10-02 10:55:35:000

In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines new draft guidance that he says should improve the process for reviewing generic drug marketing applications and boost competition in the prescription drugs market. More news on: ProShares Ultra Nasdaq Biotechnology ETF, T… read more...

FDA OKs Paratek's sarecycline for acne

via: SeekingAlpha at 2018-10-02 08:53:09:000

The FDA approves Paratek Pharmaceuticals' (NASDAQ: PRTK ) SEYSARA (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients at least nine years old. More news on: Paratek Pharmaceuticals, Inc., Allergan plc, Almirall SA, Healthcar… read more...

Turmoil In Italy Spooks Markets (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-10-02 08:02:29:000

Today's Top Stories: Italy turmoil spooks markets; Tories talk Brexit at annual conference; and GE shares soar after new CEO announcement. Click play to listen in your browser. /figure> If you are interested in listening to Wall Street Breakfast to start your day, look for us in … read more...

Wall Street Breakfast: Turmoil In Rome Spooks Markets

via: SeekingAlpha at 2018-10-02 06:57:11:000

The original version of yesterday's Wall Street Breakfast included an incorrect Economic Calendar. This has been updated. We apologize for the error. Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (cl… read more...

Allergan to Report Third Quarter 2018 Earnings and Host Conference Call and Webcast

via: PR Newswire at 2018-10-01 08:00:00:000

DUBLIN , Oct. 1, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018 , prior to the open of U.S. financial markets. Allergan will host a conference call and webcast at 8:… read more...

Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

via: PR Newswire at 2018-09-28 07:30:00:000

DUBLIN , Sept. 28, 2018 /PRNewswire/ -- In celebration of breast cancer awareness month, Allergan plc (NYSE: AGN) announced today The Allergan Foundation's continuing commitment to breast health, awareness, restoration, and research through a $2,000,000 pledge to be paid over the next t… read more...

Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

via: PR Newswire at 2018-09-28 07:30:00:000

DUBLIN , Sept. 28, 2018 /PRNewswire/ -- In celebration of breast cancer awareness month, Allergan plc (NYSE: AGN) announced today The Allergan Foundation's continuing commitment to breast health, awareness, restoration, and research through a $2,000,000 pledge to be paid over the next t… read more...

Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

via: PR Newswire at 2018-09-28 07:30:00:000

DUBLIN , Sept. 28, 2018 /PRNewswire/ -- In celebration of breast cancer awareness month, Allergan plc (NYSE: AGN) announced today The Allergan Foundation's continuing commitment to breast health, awareness, restoration, and research through a $2,000,000 pledge to be paid over the next t… read more...

Tiziana Life Sciences Plans To Raise $16 Million In U.S. IPO

via: SeekingAlpha at 2018-09-27 13:16:07:000

Quick Take Tiziana Life Sciences plc ( TLSA ) is seeking to raise $16 million in a U.S. IPO, according to an amended registration statement . The company is advancing a pipeline of therapeutic candidates for various cancers and immune diseases. TLSA is developing promising treatments … read more...

Eton Pharmaceuticals Readies Plan For $18 Million IPO

via: SeekingAlpha at 2018-09-27 12:21:20:000

Quick Take Eton Pharmaceuticals ( ETON ) intends to raise $18 million in an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of reformulations based on existing, approved treatments. ETON is a small life sciences firm with a promisin… read more...

Urovant IPO: Phase 3 Clinical Data To Be Released In 2019

via: SeekingAlpha at 2018-09-27 11:33:47:000

Conducting biopharmaceutical research initiated by Merck ( MRK ) and with a massive market opportunity, Urovant ( UROV ) seems an interesting name to be followed once the IPO goes live. With that, the facts that the company was incorporated in Cayman and Roivant Sciences Ltd. controls the comp… read more...

Allergan announces FDA acceptance of supplemental new drug application for VRAYLAR

via: SeekingAlpha at 2018-09-26 08:12:12:000

Allergan plc (NYSE: AGN ) announced that US FDA has accepted for review the supplemental New Drug Application for VRAYLAR (cariprazine), seeking to expand the indication to include the treatment of depressive episodes associated with bipolar I disorder in adults in the current product label…. read more...

Allergan Announces FDA Acceptance of Supplemental New Drug Application For VRAYLAR® (cariprazine)

via: PR Newswire at 2018-09-26 07:30:00:000

DUBLIN , Sept. 26, 2018 /PRNewswire/ -- Allergan plc(NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine)… read more...

Pfizer facing difficult path to ramp up biosimilar business

via: SeekingAlpha at 2018-09-25 15:51:13:000

In an entirely predictable scenario, Pfizer ( PFE -0.3% ) is encountering a broad range of competitive roadblocks in its efforts to gain traction in its biosimilar business, a strategic priority since acquiring Hospira for $17B in 2015. More news on: Pfizer Inc., Amgen Inc., Johnson &amp… read more...

Express Scripts taking credit for Gilead's planned launch of generic HCV meds

via: SeekingAlpha at 2018-09-24 16:02:45:000

Express Scripts ( ESRX -0.2% ) is congratulating the organization it sees in the mirror over Gilead Sciences' plan to launch generic versions of HCV meds Epclusa and Harvoni. More news on: Express Scripts, Inc., Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthca… read more...

Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st

via: PR Newswire at 2018-09-20 07:30:00:000

DUBLIN , Sept. 20, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced a partnership with actor Scott Eastwood in honor of World Alzheimer's Day, September 21 , a day used as a focal point by organizations globally to raise awareness for Alzheimer's disease and the sacri… read more...

Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st

via: PR Newswire at 2018-09-20 07:30:00:000

DUBLIN , Sept. 20, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced a partnership with actor Scott Eastwood in honor of World Alzheimer's Day, September 21 , a day used as a focal point by organizations globally to raise awareness for Alzheimer's disease and the sacri… read more...

Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st

via: PR Newswire at 2018-09-20 07:30:00:000

DUBLIN , Sept. 20, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced a partnership with actor Scott Eastwood in honor of World Alzheimer's Day, September 21 , a day used as a focal point by organizations globally to raise awareness for Alzheimer's disease and the sacri… read more...

Allergan Announces Plans to Build First Medical Aesthetics Innovation Center in Chengdu China

via: PR Newswire at 2018-09-19 08:53:00:000

-- Innovation Center to Feature State-of-the-Art Medical Aesthetics Training Center for Practitioners, Education and Experience Center for Consumer s -- Allergan Expects to Train 3,000 Medical Aesthetics Practitioners Per Year Through New Cente r -- Announcement Follows Recent Mem… read more...

Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots

via: SeekingAlpha at 2018-09-18 15:02:16:000

Recently, Allergan ( AGN ) announced that it had made a deal to purchase a biotech named Bonti . This buyout was established so that Allergan could get it hands on an aesthetic product that is nearly similar to that of one of its top-selling drugs, Botox. This is good news in that it prot… read more...

Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved

via: SeekingAlpha at 2018-09-18 10:45:37:000

Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticalss ( ALNY ) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation . Left… read more...

House nixes drug prices in TV ads

via: SeekingAlpha at 2018-09-17 11:50:23:000

The U.S. House of Representatives breaks with the Senate on a bill that included an amendment requiring drug makers to include list prices in TV drug advertisements. The bipartisan bill passed the Senate a few weeks ago but the House stripped out the price disclosure amendment. More news… read more...

Allergan's Botox shows treatment benefit at higher doses

via: SeekingAlpha at 2018-09-14 16:37:16:000

Study results showed that higher doses of Allergan's (NYSE: AGN ) BOTOX (onabotulinumtoxinA) produced statistically significantly better results than the currently approved total dose in patients with moderate-to-severe frown lines. A greater proportion of patients receiving 40, 60 or 80 … read more...

Allergan's Botox shows treatment benefit at higher doses

via: SeekingAlpha at 2018-09-14 16:37:16:000

Study results showed that higher doses of Allergan's (NYSE: AGN ) BOTOX (onabotulinumtoxinA) produced statistically significantly better results than the currently approved total dose in patients with moderate-to-severe frown lines. A greater proportion of patients receiving 40, 60 or 80 … read more...

Allergan's Botox shows treatment benefit at higher doses

via: SeekingAlpha at 2018-09-14 16:37:16:000

Study results showed that higher doses of Allergan's (NYSE: AGN ) BOTOX (onabotulinumtoxinA) produced statistically significantly better results than the currently approved total dose in patients with moderate-to-severe frown lines. A greater proportion of patients receiving 40, 60 or 80 … read more...

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines

via: PR Newswire at 2018-09-14 16:15:00:000

DUBLIN , Sept. 14, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced clinical study results of higher doses of BOTOX Cosmetic compared to BOTOX Cosmetic20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan co… read more...

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines

via: PR Newswire at 2018-09-14 16:15:00:000

DUBLIN , Sept. 14, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced clinical study results of higher doses of BOTOX Cosmetic compared to BOTOX Cosmetic20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan co… read more...

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines

via: PR Newswire at 2018-09-14 16:15:00:000

DUBLIN , Sept. 14, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced clinical study results of higher doses of BOTOX Cosmetic compared to BOTOX Cosmetic20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan co… read more...

Allergan Highlights Key Growth Drivers for Medical Aesthetics

via: PR Newswire at 2018-09-14 15:00:00:000

DUBLIN , Sept. 14, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today hosted its first ever Medical Aesthetics Analyst Day where the Company outlined its industry-leading portfolio and pipeline and key initiatives to drive future growth, as well as presented an overview of the globa… read more...

Allergan Highlights Key Growth Drivers for Medical Aesthetics

via: PR Newswire at 2018-09-14 15:00:00:000

DUBLIN , Sept. 14, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today hosted its first ever Medical Aesthetics Analyst Day where the Company outlined its industry-leading portfolio and pipeline and key initiatives to drive future growth, as well as presented an overview of the globa… read more...

Allergan Highlights Key Growth Drivers for Medical Aesthetics

via: PR Newswire at 2018-09-14 15:00:00:000

DUBLIN , Sept. 14, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today hosted its first ever Medical Aesthetics Analyst Day where the Company outlined its industry-leading portfolio and pipeline and key initiatives to drive future growth, as well as presented an overview of the globa… read more...

Allergan bullish on aesthetics business, sees sales as high as $8B by 2025

via: SeekingAlpha at 2018-09-14 12:55:11:000

Allergan ( AGN -1% ) projects that its aesthetics business could double in six years according to Chief Commercial Officer Bill Meury. At its Medical Aesthetics Day in New York, he said the company expects the unit to generate $7B - 8B in sales by 2025 despite looming BOTOX competition f… read more...

Allergan bullish on aesthetics business, sees sales as high as $8B by 2025

via: SeekingAlpha at 2018-09-14 12:55:11:000

Allergan ( AGN -1% ) projects that its aesthetics business could double in six years according to Chief Commercial Officer Bill Meury. At its Medical Aesthetics Day in New York, he said the company expects the unit to generate $7B - 8B in sales by 2025 despite looming BOTOX competition f… read more...

Allergan bullish on aesthetics business, sees sales as high as $8B by 2025

via: SeekingAlpha at 2018-09-14 12:55:11:000

Allergan ( AGN -1% ) projects that its aesthetics business could double in six years according to Chief Commercial Officer Bill Meury. At its Medical Aesthetics Day in New York, he said the company expects the unit to generate $7B - 8B in sales by 2025 despite looming BOTOX competition f… read more...

Allergan to acquire Bonti for $195M

via: SeekingAlpha at 2018-09-14 09:26:32:000

Allergan (NYSE: AGN ) has agreed to acquire Newport Beach, CA-based Bonti , a developer of fast-acting neurotoxin treatments for aesthetic and therapeutic applications. More news on: Allergan plc, Healthcare stocks news, Consumer stocks news, Merger & acquisition news, Read more… read more...

Allergan to acquire Bonti for $195M

via: SeekingAlpha at 2018-09-14 09:26:32:000

Allergan (NYSE: AGN ) has agreed to acquire Newport Beach, CA-based Bonti , a developer of fast-acting neurotoxin treatments for aesthetic and therapeutic applications. More news on: Allergan plc, Healthcare stocks news, Consumer stocks news, Merger & acquisition news, Read more… read more...

Allergan to acquire Bonti for $195M

via: SeekingAlpha at 2018-09-14 09:26:32:000

Allergan (NYSE: AGN ) has agreed to acquire Newport Beach, CA-based Bonti , a developer of fast-acting neurotoxin treatments for aesthetic and therapeutic applications. More news on: Allergan plc, Healthcare stocks news, Consumer stocks news, Merger & acquisition news, Read more… read more...

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

via: PR Newswire at 2018-09-14 09:15:00:000

DUBLIN and NEWPORT BEACH, Calif. , Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercializati… read more...

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

via: PR Newswire at 2018-09-14 09:15:00:000

DUBLIN and NEWPORT BEACH, Calif. , Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercializati… read more...

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

via: PR Newswire at 2018-09-14 09:15:00:000

DUBLIN and NEWPORT BEACH, Calif. , Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercializati… read more...

Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September

via: SeekingAlpha at 2018-09-12 14:40:23:000

Actionable Conclusions (1-10): Analysts Projected 13.4% To 72.2% Net Gains For Top Ten Healthcare WallStars By September 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices…. read more...

Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September

via: SeekingAlpha at 2018-09-12 14:40:23:000

Actionable Conclusions (1-10): Analysts Projected 13.4% To 72.2% Net Gains For Top Ten Healthcare WallStars By September 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices…. read more...

Allergan Unveils Spotlyte(TM), A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments

via: PR Newswire at 2018-09-12 07:30:00:000

DUBLIN , Sept. 12, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced the launch of Spotlyte an innovativedigital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Through well-res… read more...

Allergan Unveils Spotlyte(TM), A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments

via: PR Newswire at 2018-09-12 07:30:00:000

DUBLIN , Sept. 12, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced the launch of Spotlyte an innovativedigital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Through well-res… read more...

Revance Therapeutics: A New Contender In The Botox Arena

via: SeekingAlpha at 2018-09-10 11:58:53:000

Editor's note: Seeking Alpha is proud to welcome Charles Santoro as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Pipeli… read more...

Revance Therapeutics: A New Contender In The Botox Arena

via: SeekingAlpha at 2018-09-10 11:58:53:000

Editor's note: Seeking Alpha is proud to welcome Charles Santoro as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Pipeli… read more...

Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potential Market Dominance

via: SeekingAlpha at 2018-09-10 08:00:00:000

Over the past year, interest has heated up in the biotech industry about NASH, with analysts estimating market size in 2025 anywhere between $20-35 billion. Positive Phase 2 data readouts for Madrigal (NASDAQ: MDGL ) and Galmed (NASDAQ: GLMD ) caused both stocks to more than double overnight… read more...

Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potential Market Dominance

via: SeekingAlpha at 2018-09-10 08:00:00:000

Over the past year, interest has heated up in the biotech industry about NASH, with analysts estimating market size in 2025 anywhere between $20-35 billion. Positive Phase 2 data readouts for Madrigal (NASDAQ: MDGL ) and Galmed (NASDAQ: GLMD ) caused both stocks to more than double overnight… read more...

Allergan to Host Medical Aesthetics Day Event on September 14, 2018

via: PR Newswire at 2018-09-10 08:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it will host a Medical Aesthetics Day event and webcast on Friday, September 14, 2018 . The investor event will include presentations on Allergan's industr… read more...

Allergan to Host Medical Aesthetics Day Event on September 14, 2018

via: PR Newswire at 2018-09-10 08:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it will host a Medical Aesthetics Day event and webcast on Friday, September 14, 2018 . The investor event will include presentations on Allergan's industr… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

The Most Exciting Advance in Skincare is Here: Introducing the SkinMedica® LUMIVIVE(TM) System

via: PR Newswire at 2018-09-06 09:00:00:000

DUBLIN , Sept. 6, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced the launch of the new SkinMedica LUMIVIVE System, an innovative skincare product designed with two distinct formulas - one to shield skin from blue light and environmental aggressors… read more...

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-06 02:48:58:000

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitzs 13F portfolio on a quarterly basis. It is based on Weitzs regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Wallace Weitzs Weitz Investment Manag… read more...

Allergan PLC (AGN) CEO Brent Saunders Presents at 2018 Wells Fargo Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-09-05 15:05:08:000

Allergan PLC (AGN) 2018 Wells Fargo Healthcare Conference Call September 05, 2018 09:05 AM ET Executives Brent Saunders - Chief Executive Officer Analysts David Maris - Wells Fargo Securities Presentation David Maris I will come join you on the couch in a second. But … read more...

Allergan to Present at the 2018 Morgan Stanley Global Healthcare Conference

via: PR Newswire at 2018-09-04 08:00:00:000

DUBLIN , Sept. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Morgan Stanley Global Healthcare Conference in New York, NY . The presentati… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-04 02:08:11:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins 13F portfolio on a quarterly basis. It is based on Hawkins regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Mason Hawkins Southeastern Asset Ma… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-03 12:05:42:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins' 13F portfolio on a quarterly basis. It is based on Robbins' regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Larry Robbins' Glenview Capital Management Portfolio artic… read more...

Tracking David Tepper's Appaloosa Management Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-03 07:47:28:000

This article is part of a series that provides an ongoing analysis of the changes made to David Teppers 13F portfolio on a quarterly basis. It is based on Appaloosa Managements regulatory 13F Form filed on 08/14/2018. Please visit our Tracking David Teppers Appaloosa… read more...

Tracking John Paulson's Paulson & Company Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-02 14:57:04:000

This article is part of a series that provides an ongoing analysis of the changes made to John Paulsons 13F stock portfolio on a quarterly basis. It is based on Paulsons regulatory 13F Form filed on 08/14/2018. Please visit our Tracking John Paulsons Paulson & Co… read more...

Big Pharma in the red after AstraZeneca lupus flop

via: SeekingAlpha at 2018-08-31 13:41:52:000

Big Pharma is getting roughed up today. This morning, AstraZeneca ( AZN -1.7% ) announced that one of its main drivers of expected future growth failed a late-stage lupus study. More news on: AstraZeneca Group plc, Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks ne… read more...

Big Pharma in the red after AstraZeneca lupus flop

via: SeekingAlpha at 2018-08-31 13:41:52:000

Big Pharma is getting roughed up today. This morning, AstraZeneca ( AZN -1.7% ) announced that one of its main drivers of expected future growth failed a late-stage lupus study. More news on: AstraZeneca Group plc, Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks ne… read more...

Allergan to Present at the 2018 Wells Fargo Healthcare Conference

via: PR Newswire at 2018-08-30 08:00:00:000

DUBLIN , Aug. 30, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Wells Fargo Healthcare Conference in Boston, Massachusetts . The presen… read more...

Allergan Continues Board Refreshment Process

via: PR Newswire at 2018-08-29 17:00:00:000

DUBLIN , Aug. 29, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Paul Bisaro will be retiring from its Board of Directors, as part of the company's ongoing board refreshment process. Mr. Bisaro has served on the board of directors since 2007 when he joined Watson Lab… read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA accepts Evolus' refiled BLA for frown line med prabotulinumtoxinA, action date February 2, 2019

via: SeekingAlpha at 2018-08-29 09:04:00:000

The FDA accepts for review Evolus' (NASDAQ: EOLS ) resubmitted marketing application seeking approval for prabotulinumtoxinA (DWP-450) for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults under the age of 65. The agency's action date is February 2, 20… read more...

FDA clamps down on opioid-peddling websites

via: SeekingAlpha at 2018-08-28 10:57:45:000

The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc… read more...

Genfit And Elafibranor In NASH Fibrosis: A Revisit Of The FDA Guidelines

via: SeekingAlpha at 2018-08-27 08:58:53:000

Leadership is solving problems - Colin Powell Investment Thesis In 2015, the stock price of Genfit (GNFTF) stumbled on the release of the top line data of the Phase 2b GOLDEN-505 study of elafibranor therapy in NASH due to misinterpretation of the results. However, reanalysis of th… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

Biotech Analysis Central Pharma News: Allergan's CRL, Tonix Pharmaceutical's Potential Reversal, AstraZeneca's Tagrisso Win

via: SeekingAlpha at 2018-08-24 09:12:08:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Allergan Receives Complete Response Letter For Uterine Fibroid Drug News: Recently, Allergan ( AGN ) announced that it had received a complete resp… read more...

Biotech Analysis Central Pharma News: Allergan's CRL, Tonix Pharmaceutical's Potential Reversal, AstraZeneca's Tagrisso Win

via: SeekingAlpha at 2018-08-24 09:12:08:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Allergan Receives Complete Response Letter For Uterine Fibroid Drug News: Recently, Allergan ( AGN ) announced that it had received a complete resp… read more...

Biotech Analysis Central Pharma News: Allergan's CRL, Tonix Pharmaceutical's Potential Reversal, AstraZeneca's Tagrisso Win

via: SeekingAlpha at 2018-08-24 09:12:08:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Allergan Receives Complete Response Letter For Uterine Fibroid Drug News: Recently, Allergan ( AGN ) announced that it had received a complete resp… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Your Daily Pharma Scoop: Audentes's New Designation, Esmya Rejected, Agilent Approved

via: SeekingAlpha at 2018-08-23 08:00:00:000

Stocks in News: BOLD, AGN Audentes gene therapy AT132 nabs special FDA designation for rare muscle weakness disorder Discussions: Audentes Therapeutics' ( BOLD ) AT132 receives FDA designation of a Regenerative Medicine Advanced Therapy (RMAT). The therapy is indicated… read more...

FDA awards contract to develop guidelines for opioid prescribing

via: SeekingAlpha at 2018-08-22 11:16:23:000

The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND… read more...

Allergan's Esmya fibroid treatment rejected by FDA

via: SeekingAlpha at 2018-08-21 18:36:53:000

Allergan (NYSE: AGN ) -1.6% after-hours on news that the Food and Drug Administration rejected the company's Esmya treatment for uterine fibroids, requesting more information and citing safety issues outside the U.S. More news on: Allergan plc, Healthcare stocks news, Stocks on the mov… read more...

Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Ulipristal Acetate New Drug Application

via: PR Newswire at 2018-08-21 17:00:00:000

DUBLIN , Aug.21, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for ulipristal acetate (UPA)for the treatment of abnorm… read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

via: SeekingAlpha at 2018-08-17 05:00:00:000

Ironwood Pharmaceuticals ( IRWD ) recently came under pressure as Dr. Alex Denner of activist hedge fund Sarissa Capital attempted to secure a seat on the board of directors. While he was unsuccessful in this endeavor, Ironwood reacted by announcing that it would separate into two entities: … read more...

Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

via: SeekingAlpha at 2018-08-17 05:00:00:000

Ironwood Pharmaceuticals ( IRWD ) recently came under pressure as Dr. Alex Denner of activist hedge fund Sarissa Capital attempted to secure a seat on the board of directors. While he was unsuccessful in this endeavor, Ironwood reacted by announcing that it would separate into two entities: … read more...

Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

via: SeekingAlpha at 2018-08-17 05:00:00:000

Ironwood Pharmaceuticals ( IRWD ) recently came under pressure as Dr. Alex Denner of activist hedge fund Sarissa Capital attempted to secure a seat on the board of directors. While he was unsuccessful in this endeavor, Ironwood reacted by announcing that it would separate into two entities: … read more...

Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

via: SeekingAlpha at 2018-08-17 05:00:00:000

Ironwood Pharmaceuticals ( IRWD ) recently came under pressure as Dr. Alex Denner of activist hedge fund Sarissa Capital attempted to secure a seat on the board of directors. While he was unsuccessful in this endeavor, Ironwood reacted by announcing that it would separate into two entities: … read more...

White House proposing cuts in opioid production

via: SeekingAlpha at 2018-08-16 15:24:55:000

Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...

Allergan goes ex-dividend tomorrow

via: SeekingAlpha at 2018-08-15 09:21:23:000

Allergan (NYSE: AGN ) had declared $0.72/share quarterly dividend , in line with previous. More news on: Allergan plc, Dividend News, Read more … read more...

Here are 3 top drug stock ideas from JP Morgan - including Merck

via: CNBC at 2018-08-14 14:56:00:000

No summary available. read more...

Eton Pharmaceuticals Files For U.S. IPO

via: SeekingAlpha at 2018-08-14 14:25:44:000

Quick Take Eton Pharmaceuticals ( ETON ) intends to raise $21 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing a pipeline of previously-approved treatment candidates in new formulations. When we learn more details from manageme… read more...

Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update

via: SeekingAlpha at 2018-08-14 05:08:29:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 08/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Broyhill Asset Management Mid-Year Letter 2018

via: SeekingAlpha at 2018-08-13 07:30:00:000

Originally posted on Read more … read more...

Stocks To Watch: Any Privacy For Tesla?

via: SeekingAlpha at 2018-08-11 09:07:58:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...

Stocks To Watch: Any Privacy For Tesla?

via: SeekingAlpha at 2018-08-11 09:07:58:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...

Are Drug Stocks Starved Of Capital?

via: SeekingAlpha at 2018-08-10 15:39:34:000

By Sam Peters, CFA Prevailing Drug Narrative Leaves Room for Improvement With mundane cyclical risks, such as U.S. dollar strength, and scarier structural risks, such as a real trade war, on the radar, it becomes increasingly important to position portfolios where the prevailing market n… read more...

FDA OKs birth control app

via: SeekingAlpha at 2018-08-10 12:24:30:000

The FDA has approved a smartphone app called Natural Cycles which uses an algorithm to calculate the days of the month a women is likely to be fertile, based on body temperature readings and menstrual cycle information. This method of birth control, referred to as "fertility awareness," is… read more...

U.S. Moats Ahead Despite IT Underweight

via: SeekingAlpha at 2018-08-09 07:58:03:000

For the month Ending July 30, 2018 Performance Overview Domestic moat companies, as represented by the Morningstar Wide Moat Focus IndexSM ( MWMFTR, or "U.S. Moat Index" ), once again posted strong results in July, outperforming the S&P 500 Index (4.11% vs. 3.72%, respectively) and pul… read more...

Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-08-08 09:35:34:000

This article is part of a series that provides an ongoing analysis of the changes made to William Von Muefflings 13F stock portfolio on a quarterly basis. It is based on Muefflings regulatory 13F Form filed on 08/07/2018. Please visit our Tracking William Von Mueffling's C… read more...

Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process

via: PR Newswire at 2018-08-08 08:03:00:000

DUBLIN , Aug. 8, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced that Michael E. Greenberg , PhD will join its Board of Directors effective immediately , as part of the company's ongoing board refreshment process. Dr. Greenberg is the Nathan Marsh Pusey Professor… read more...

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

via: PR Newswire at 2018-08-06 16:01:00:000

DUBLINand CAMBRIDGE, Mass. , Aug. 6, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceu… read more...

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

via: PR Newswire at 2018-08-06 16:01:00:000

DUBLINand CAMBRIDGE, Mass. , Aug. 6, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceu… read more...

BioDelivery Sciences: Buy The Dip

via: SeekingAlpha at 2018-08-06 14:01:39:000

Shares of BioDelivery Sciences ( BDSI ) at one point rose by more than 75% after my mid-May article pointed out its viability as a turnaround play at 52-week lows. With recent volatility in the biotech sector, the resulting pullback appears a prime opportunity to initiate to or add to po… read more...

BioDelivery Sciences: Buy The Dip

via: SeekingAlpha at 2018-08-06 14:01:39:000

Shares of BioDelivery Sciences ( BDSI ) at one point rose by more than 75% after my mid-May article pointed out its viability as a turnaround play at 52-week lows. With recent volatility in the biotech sector, the resulting pullback appears a prime opportunity to initiate to or add to po… read more...

Your Daily Pharma Scoop: Epizyme Down, MiMedx Proceeds, Summit Beats

via: SeekingAlpha at 2018-08-05 03:53:18:000

Stocks in News: EPZM, MDXG Epizyme down 8% premarket on termination of tazemetostat in DLBCL & delay in NDA filing for ES Discussion : Epizyme ( EPZM ) announced the termination of the development program of tazemetostat in diffuse large B-cell lymphoma (DLBCL). Main reaso… read more...

Stocks To Watch: Meet The New Ford

via: SeekingAlpha at 2018-08-04 08:42:14:000

Stocks To Watch: Meet The New Ford Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors head into next week with a bit of mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-03 07:56:22:000

Pacira Pharmaceuticals (NASDAQ: PCRX ) upgraded to Buy with a $54 (26% upside) price target at Needham. More news on: Pacira Pharmaceuticals, Inc., Nu Skin Enterprises Inc., Mednax, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Allergan sues Pfizer in attempt to sidestep potential damages from opioid crisis litigation

via: SeekingAlpha at 2018-08-02 15:15:35:000

Aimed at covering the potential payouts from lawsuits related to the opioid crisis, Allergan ( AGN +0.2% ) sues Pfizer ( PFE -1.4% ) over alleged improper sales and marketing of KADIAN (morphine), the rights to which it acquired in 2008 from a company later acquired by Pfizer. More… read more...

Evolus refiles U.S. marketing application for prabotulinumtoxinA

via: SeekingAlpha at 2018-08-02 07:56:41:000

Evolus (NASDAQ: EOLS ) announces that it is resubmitting its BLA today seeking approval for DWP-450 (prabotulinumtoxinA) for the treatment of moderate-to-severe frown lines. The company received a CRL in May citing the need for additional CMC information. More news on: Evolus, Inc., Alle… read more...

Wall Street Favorite Healthcare Equities For July Topped By CVS Health

via: SeekingAlpha at 2018-08-01 02:27:38:000

Actionable Conclusions (1-10): Analysts Projected 12.6% To 28.5% Net Gains For Top Ten Healthcare WallStars By July 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (The… read more...

Tiziana Life Sciences Files For Small IPO

via: SeekingAlpha at 2018-07-31 14:49:30:000

Quick Take Tiziana Life Sciences ( TLSA ) intends to raise gross proceeds of $11.5 million from a U.S. IPO, according to an F-1 registration statement . The firm is developing therapeutics and diagnosis for cancers and immune diseases. TLSA is preparing for Phase 3 trials for its le… read more...

Allergan: Using Options To Leverage Any Upside

via: SeekingAlpha at 2018-07-31 12:04:18:000

Allergan ( AGN ) looks to be reversing higher following years of decline. The company is experiencing continued growth with its main offerings, while also improving its political capital, and keeping a united front with its management. Although its debt burden is elevated, the company is t… read more...

Pfizer's Read thinks drug rebates going bye-bye in U.S.

via: SeekingAlpha at 2018-07-31 11:45:57:000

In this morning's earnings call, Pfizer ( PFE +3% ) chief Ian Read said he believes the Trump administration plans to eliminate rebates on prescription drug purchases, although he has no clear idea when such a policy would be implemented. More news on: Pfizer Inc., Health Care Select S… read more...

U.S. healthcare spending nearing 20% of GDP

via: SeekingAlpha at 2018-07-31 11:25:57:000

The WSJ reports that healthcare spending in the U.S. will soon reach 20% of GDP, a significantly higher proportion than any other major economy. The key cost driver has been price hikes, not increased demand. Since 1960, the CPI has risen ~700% while medical costs have risen 2,000%. Since … read more...

Six Flags Entertainment Is A Buy - Cramer's Lightning Round (7/30/18)

via: SeekingAlpha at 2018-07-31 07:18:53:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, July 30. Bullish Calls Six Flags Entertainment (SIX): The company's last quarter was better than many others'. It's a buy. Procter & Gamble (PG): Nelson Peltz is on the board, and the stock… read more...

Earnings, Tariffs and Video Games in the Blitz

via: CNBC at 2018-07-31 06:21:00:000

No summary available. read more...

Cramer's lightning round: Buy into Allergan's roaring stock below $180

via: CNBC at 2018-07-30 18:50:00:000

No summary available. read more...

Allergan: So Many Ways To Win

via: SeekingAlpha at 2018-07-30 15:10:19:000

Allergan ( AGN ) recently released its financial results for the quarter ending June 30 th . The drug company generated revenues of 4.1$ billion, beating consensus by 180$ million. On the bottom line, Allergan reported earnings of 4.42$ per share, beating the consensus by 29 cents per share…. read more...

Allergan Announces Third Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share

via: PR Newswire at 2018-07-30 08:00:00:000

DUBLIN , July 30, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced the record and payment dates for a cash dividend of $0.72 per ordinary share for the third quarter of 2018. The dividend will be paid on September 17, 2018 to shareholders of record at the close of bu… read more...

Stocks To Watch: Apple, Harley And Tesla On The Marquee

via: SeekingAlpha at 2018-07-28 08:27:37:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Will Apple (AAPL) percolate right along after earnings unlike the tracks of Faceboo… read more...

Stocks To Watch: Apple, Harley And Tesla On The Marquee

via: SeekingAlpha at 2018-07-28 08:27:37:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Will Apple (AAPL) percolate right along after earnings unlike the tracks of Faceboo… read more...

Economists Foresee Bumper GDP (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-07-27 07:34:33:000

Editor's note: Seeking Alpha is proud to welcome WSB Podcast as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Today's top … read more...

Wall Street Breakfast: Economists Foresee Bumper GDP

via: SeekingAlpha at 2018-07-27 06:57:36:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The headliner of this action-packed week could come from the latest GDP reading, the official scorecard of the U.S…. read more...

Allergan Plc (AGN) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 14:53:24:000

Allergan Plc (AGN) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Daphne Karydas - Allergan Plc Brenton L. Saunders - Allergan Plc William J. Meury - Allergan Plc C. David Nicholson - Allergan Plc Matthew M. Walsh - Allergan Plc Analysts Aharon Gal - Sanford … read more...

Allergan plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 14:04:50:000

The following slide deck was published by Allergan plc in conjunction with their 2018 Q2 earnings Read more … read more...

Allergan Q2 top line up 3%; non-GAAP EPS up 10%; raises fiscal guidance

via: SeekingAlpha at 2018-07-26 09:28:42:000

Allergan ( AGN ) Q2 results : Revenues: $4,124.2M (+2.9%); US Specialized Therapeutics: $1,826.7M (+6.5%); US General Medicine: $1,320M (-7.5%); International: $948.9M (+10.5%); Corporate: $3.6M (-41.9%). More news on: Allergan plc, Healthcare stocks news, Earnings news and commentary, … read more...

Longleaf Partners Shareholder Letter Q2 2018

via: SeekingAlpha at 2018-07-26 07:05:51:000

Read more … read more...

Allergan beats by $0.29, beats on revenue

via: SeekingAlpha at 2018-07-26 06:33:38:000

Allergan (NYSE: AGN ): Q2 EPS of $4.42 beats by $0.29 . More news on: Allergan plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Allergan Reports Strong Second Quarter 2018 Results Including GAAP Net Revenues of $4.1 Billion

via: PR Newswire at 2018-07-26 06:30:00:000

DUBLIN , July 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its second quarter 2018 performance. Total second quarter 2018 GAAP net revenues were $4.12 billion , a 2.9 percent increase from the prior year quarter. SECOND QUARTER 2018 Executiv… read more...

Nasdaq sheds 1% as Facebook leads tech plunge, Dow adds more than 100 points

via: CNBC at 2018-07-26 05:08:00:000

No summary available. read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-07-25 17:30:13:000

AAL , AAN , AB , ABMD , ADNT , AGN , AIMC , ALK , ALKS , ALLE , ALLY , ALXN , APD , ARD , ASPS , AUO , AXE , AXTA , AZN , BANC , BAX , BC , BMS , BMY , BUD , BWA , CELG , CFR , CMCSA , CME , CMS , CNHI , COLB , COP , COR , COWN , CPG , CRI , CRR , CTS… read more...

Trump/Juncker In Trade Talks (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-07-25 07:37:39:000

Today's top stories: Trump/Juncker in trade talks; EU reciprocal tariff threat; and Sergio Marchionne passes away. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alpha Podcasts here )… read more...

Wall Street Breakfast: Key Talks On U.S.-EU Trade

via: SeekingAlpha at 2018-07-25 07:01:49:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). President Trump will sit down with European Commission President Jean-Claude Juncker today to discuss trade, includ… read more...

House repeals tax on medical devices

via: SeekingAlpha at 2018-07-25 05:38:01:000

In a show of bipartisan support, the U.S. House has voted to repeal a 2.3% excise tax on medical devices, which applies to products such as pacemakers and artificial joints, not items directly sold to consumers. More news on: Johnson & Johnson, Medtronic plc, Baxter International Inc… read more...

4 Members Of The $800+ Billion Market Cap Club

via: SeekingAlpha at 2018-07-24 05:37:20:000

Below is an updated look at the 35 largest S&P 500 companies. It's worth noting that recent gains have put four companies into the $800+ billion market cap club . Apple (AAPL) is still on top with a market cap of $933 billion, followed by Amazon (AMZN) at $873 billion, Alphabet (GOOGL) at… read more...

Applied Genetic Technologies Corporation: Near-Term Run Up Expected

via: SeekingAlpha at 2018-07-23 21:52:24:000

Shares of Applied Genetic Technologies Corporation ( AGTC ) are currently trading at about a third of the original IPO pricing of $12 per share, which took place in 2014. Year-to-date the stock price has risen by roughly 30%. Chart Figure 1: AGTC daily advanced chart (Source: Finviz… read more...

Allergan's AGN-241751 Fast Track'd in U.S. for MDD

via: SeekingAlpha at 2018-07-23 08:51:56:000

The FDA designates Allergan's (NYSE: AGN ) Phase 2-stage AGN-241751 for Fast Track review for the treatment of major depressive disorder (MDD). More news on: Allergan plc, Healthcare stocks news, Read more … read more...

Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)

via: PR Newswire at 2018-07-23 08:00:00:000

DUBLIN , July 23, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has granted Fast Track designation for AGN-241751, an investigational new treatment for Major Depressive Disorder (MDD… read more...

Allergan: Inflammation Is The Reason Investors Did Not React Well To Abicipar Results

via: SeekingAlpha at 2018-07-23 01:20:08:000

Abicipar Results Appeared Positive But Stock Did Not React Well On July 19th, Allergan ( AGN ) announced (seemingly) positive top line results from its two phase 3 trials for abicipar. Recall that abicipar is for patients with neovascular (wet) age-related macular degeneration (NASDAQ: AMD… read more...

3 Things In Biotech, July 21: Does CTI Really Deserve To Tank?

via: SeekingAlpha at 2018-07-21 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche hasn't quite hit the mark in lung cancer… yet Company: Roche ( RHHBY ) ( RHHBF ) Therapy: Atezolizumab ... read more...

3 Things In Biotech, July 21: Does CTI Really Deserve To Tank?

via: SeekingAlpha at 2018-07-21 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche hasn't quite hit the mark in lung cancer… yet Company: Roche ( RHHBY ) ( RHHBF ) Therapy: Atezolizumab ... read more...

Allergan strikes out with sovereign nation scheme to protect patents

via: SeekingAlpha at 2018-07-20 16:22:11:000

The U.S. Court of Appeals has affirmed the decision of the USPTO's Patent Trial and Appeal Board that Allergan (NYSE: AGN ) cannot apply its tribal sovereign immunity to prevent inter partes review proceedings. The ruling allows Mylan's (NASDAQ: MYL ) challenge to Allergan's Restasis (cycl… read more...

Allergan holds off Novartis' generic version of Combigan

via: SeekingAlpha at 2018-07-20 12:29:32:000

Allergan ( AGN -0.7% ) prevails in its patent infringement litigation with Novartis' ( NVS +1.8% ) Sandoz unit related to glaucoma med COMBIGAN (brimonidine tartrate/timolol maleate ophthalmic solution). More news on: Allergan plc, Novartis AG, Healthcare stocks news, Stocks on the m… read more...

Allergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To Pit It Against A Host Of Competitors

via: SeekingAlpha at 2018-07-20 02:36:14:000

Recently, Allergan ( AGN ) and its partner Molecular Partners announced good news for their two phase 3 studies. It was announced that both phase 3 studies had met on their respective primary endpoints . This leads Allergan to submit a BLA for its drug abicipar to treat patients with wet … read more...

Allergan (AGN) Abicipar SEQUOIA & CEDAR Phase 3 Study Results - Slideshow

via: SeekingAlpha at 2018-07-19 14:34:33:000

The following slide deck was published by Allergan plc in conjunction with this Read more … read more...

Big Pharma in the red on ramped up pressure on drug prices

via: SeekingAlpha at 2018-07-19 11:10:23:000

Drug makers are under pressure as the Trump administration dials up the heat with its plan to corral prices. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, , News on ETFs, Read more … read more...

Allergan's abicipar on par with Lucentis in two late-stage AMD studies; shares down 2.5% on marketing app timeline

via: SeekingAlpha at 2018-07-19 10:37:27:000

Allergan ( AGN -2.5% ) and alliance partner Molecular Partners AG announce successful results from two Phase 3 clinical trials, SEQUOIA and CEDAR , evaluating abicipar pegol 8 in treatment-naive patients with neovascular age-related macular degeneration (AMD). More news on: Allergan… read more...

Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration

via: PR Newswire at 2018-07-19 08:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies, today announced the release of t… read more...

Madrigal Is Unreasonably Priced For Perfection And Limited Competition

via: SeekingAlpha at 2018-07-18 18:34:19:000

"She was here on earth to grasp the meaning of its wild enchantment, and to call each thing by its right name. By its right name." - Into The Wild I've written in depth concerning the potential and history of thyroid receptor agonists in treating NASH. There's no doubt about it - Madriga… read more...

FDA committed to easing approval path for biosimilars

via: SeekingAlpha at 2018-07-18 15:08:45:000

In remarks prepared for a presentation to the Brookings Institution, FDA Commissioner Scott Gottlieb, M.D. says the agency is committed to doing its part to reduce healthcare costs, especially as its relates to biosimilars. So far, the market impact of the 11 biosimilars approved in the U… read more...

Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts

via: SeekingAlpha at 2018-07-16 04:51:47:000

With Activist Pressure Mounting, Allergan Will Need Positive Results from Upcoming Catalysts Allergan (AGN) is sitting at a crucial period in the company's history. The stock has declined by over 45% since its peak in 2015, and activist shareholders have begun to get more involved with publi… read more...

Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts

via: SeekingAlpha at 2018-07-16 04:51:47:000

With Activist Pressure Mounting, Allergan Will Need Positive Results from Upcoming Catalysts Allergan (AGN) is sitting at a crucial period in the company's history. The stock has declined by over 45% since its peak in 2015, and activist shareholders have begun to get more involved with publi… read more...

Establishment Labs Prepares For U.S. IPO

via: SeekingAlpha at 2018-07-12 16:08:57:000

Quick Take Establishment Labs ( ESTA ) intends to raise $50 million from the sale of its common stock in an IPO, according to an amended registration statement . The company develops and sells silicone gel-filled breast implants for aesthetic and medical reconstruction applications. E… read more...

Establishment Labs Prepares For U.S. IPO

via: SeekingAlpha at 2018-07-12 16:08:57:000

Quick Take Establishment Labs ( ESTA ) intends to raise $50 million from the sale of its common stock in an IPO, according to an amended registration statement . The company develops and sells silicone gel-filled breast implants for aesthetic and medical reconstruction applications. E… read more...

Establishment Labs Prepares For U.S. IPO

via: SeekingAlpha at 2018-07-12 16:08:57:000

Quick Take Establishment Labs ( ESTA ) intends to raise $50 million from the sale of its common stock in an IPO, according to an amended registration statement . The company develops and sells silicone gel-filled breast implants for aesthetic and medical reconstruction applications. E… read more...

Drug prices still marching upward - Bloomberg

via: SeekingAlpha at 2018-07-12 12:20:07:000

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...

Drug prices still marching upward - Bloomberg

via: SeekingAlpha at 2018-07-12 12:20:07:000

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...

Drug prices still marching upward - Bloomberg

via: SeekingAlpha at 2018-07-12 12:20:07:000

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...

CEF THW: Undervalued And 10%+ Yield

via: SeekingAlpha at 2018-07-12 11:11:19:000

Tekla World Healthcare Fund ( THW ) has had a rough time since its inception on 6/26/2015. That was a down year for the healthcare sector, which was experiencing many uncertainties over the Affordable Care Act and just what may happen as now-President Trump's campaign showed signs of gaining m… read more...

CEF THW: Undervalued And 10%+ Yield

via: SeekingAlpha at 2018-07-12 11:11:19:000

Tekla World Healthcare Fund ( THW ) has had a rough time since its inception on 6/26/2015. That was a down year for the healthcare sector, which was experiencing many uncertainties over the Affordable Care Act and just what may happen as now-President Trump's campaign showed signs of gaining m… read more...

CEF THW: Undervalued And 10%+ Yield

via: SeekingAlpha at 2018-07-12 11:11:19:000

Tekla World Healthcare Fund ( THW ) has had a rough time since its inception on 6/26/2015. That was a down year for the healthcare sector, which was experiencing many uncertainties over the Affordable Care Act and just what may happen as now-President Trump's campaign showed signs of gaining m… read more...

Galmed +20% as Cantor sets Street-high target

via: SeekingAlpha at 2018-07-11 18:31:52:000

Galmed Pharmaceuticals is a top mover after hours, up 20.4% , after Cantor Fitzgerald issued a new Street-high price target of $59. More news on: Allergan plc, Madrigal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Aurinia launches mid-stage study of voclosporin in dry eye syndrome; shares up 2% after hours

via: SeekingAlpha at 2018-07-11 16:11:54:000

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiates a Phase 2 clinical trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). It will compare VOS 0.2% against Allergan's (NYSE: AGN ) RESTASIS (cyclosporine ophthalmic emulsion 0.05%) over a four-we… read more...

Big Pharma in the red after Pfizer backs away from price hikes

via: SeekingAlpha at 2018-07-11 09:54:56:000

Members of Big Pharma are down in early trade after Pfizer ( PFE -0.6% ) rolled back its planned price increases after direct intervention from President Trump. Investors apparently perceive diminished prospects for large price increases in the future for drug makers. More news on: Pfize… read more...

PepsiCo Stumped The Street - Cramer's Mad Money (7/10/18)

via: SeekingAlpha at 2018-07-11 07:40:22:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday , July 10. As earnings season kicked off, PepsiCo (PEP) surprised the street with strong earnings . Recently, consumer packaged goods stocks, including Pepsi, had attracted short sellers, who were… read more...

Cramer: Don't get your hopes up with the stock of Botox maker Allergan

via: CNBC at 2018-07-10 18:33:00:000

No summary available. read more...

Pricing transparency law in California having effect, drug makers nix planned increases

via: SeekingAlpha at 2018-07-10 16:12:53:000

Bloomberg reports that some drug firms have axed plans to increase pricing for certain products or have rolled back hikes in response to a new law in California aimed at pricing transparency. The law, requiring drug makers to give advance notice of significant price increases, is designed … read more...

Allergan Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Drops

via: PR Newswire at 2018-07-10 08:00:00:000

DUBLIN , July 10, 2018 /PRNewswire/ --Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced the launch of a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. The first and only artificial tear in the… read more...

Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate

via: SeekingAlpha at 2018-07-06 14:02:45:000

For myself I am an optimist-it does not seem to be much use being anything else - Winston Churchill Investment Thesis Scientifically, Cenicriviroc ((CVC)), claim to fame occurred in 2016 when it was acquired from Tobira Therapeutics by Allergan (AGN) following &#x… read more...

Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate

via: SeekingAlpha at 2018-07-06 14:02:45:000

For myself I am an optimist-it does not seem to be much use being anything else - Winston Churchill Investment Thesis Scientifically, Cenicriviroc ((CVC)), claim to fame occurred in 2016 when it was acquired from Tobira Therapeutics by Allergan (AGN) following &#x… read more...

Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate

via: SeekingAlpha at 2018-07-06 14:02:45:000

For myself I am an optimist-it does not seem to be much use being anything else - Winston Churchill Investment Thesis Scientifically, Cenicriviroc ((CVC)), claim to fame occurred in 2016 when it was acquired from Tobira Therapeutics by Allergan (AGN) following &#x… read more...

Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate

via: SeekingAlpha at 2018-07-06 14:02:45:000

For myself I am an optimist-it does not seem to be much use being anything else - Winston Churchill Investment Thesis Scientifically, Cenicriviroc ((CVC)), claim to fame occurred in 2016 when it was acquired from Tobira Therapeutics by Allergan (AGN) following &#x… read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-07-05 18:47:10:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive Summary Biotechnology is undervalued regarding historical averages in 2 metrics: price/earn… read more...

Insurers making headway on corralling drug costs with copay accumulators

via: SeekingAlpha at 2018-07-05 09:24:45:000

Reuters reports that drug makers are "scrambling" to limit the financial impact of copay accumulator programs by insurers and pharmacy benefit managers (PBMs). The scheme, which forces drug manufacturers to pony up more money to assist patients with copay costs or face declining demand for… read more...

Traders: here's how to be positioned for the second half

via: CNBC at 2018-07-03 14:41:00:000

No summary available. read more...

Traders: here's how to be positioned for the second half

via: CNBC at 2018-07-03 14:41:00:000

No summary available. read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

FDA withdraws draft guidance related to biosimilar development

via: SeekingAlpha at 2018-07-02 12:59:00:000

The FDA has withdrawn its draft guidance on statistical methods to assess analytical similarity between biosimilars and reference drugs after receiving public comments and a lone citizen petition from Pharmaceutical Scientist founder Sarfaraz Niazi, an adjunct professor at the University o… read more...

Dermira May Provide Some Upside Potential, Even After Latest FDA Approval

via: SeekingAlpha at 2018-07-02 05:29:10:000

Recently, Dermira ( DERM ) announced that it had received FDA approval for its drug Qbrexza to treat patients with Primary axillary hyperhidrosis. This latest FDA approval is the start of a turnaround for the company, but there is something else in the pipeline that could turn things aro… read more...

Allergan's Study in Chronic Migraine Receives Migraine Research Award at the American Headache Society's 60th Annual Scientific Meeting

via: PR Newswire at 2018-06-28 08:01:00:000

DUBLIN , June 28, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that the Company's sponsored CaMEO (Chronic Migraine Epidemiology and Outcomes) study is being recognized with the 2018 Harold G. Wolff Lecture Award for its c… read more...

Allergan's Study in Chronic Migraine Receives Migraine Research Award at the American Headache Society's 60th Annual Scientific Meeting

via: PR Newswire at 2018-06-28 08:01:00:000

DUBLIN , June 28, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that the Company's sponsored CaMEO (Chronic Migraine Epidemiology and Outcomes) study is being recognized with the 2018 Harold G. Wolff Lecture Award for its c… read more...

Allergan's Study in Chronic Migraine Receives Migraine Research Award at the American Headache Society's 60th Annual Scientific Meeting

via: PR Newswire at 2018-06-28 08:01:00:000

DUBLIN , June 28, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that the Company's sponsored CaMEO (Chronic Migraine Epidemiology and Outcomes) study is being recognized with the 2018 Harold G. Wolff Lecture Award for its c… read more...

Allergan Needs To Stay Focused On The Long Term

via: SeekingAlpha at 2018-06-28 07:49:59:000

Allergan (AGN) wants to strike while the iron's hot and roll out its CoolSculpting technology into international markets as quickly as possible. The objective is to set up international markets like the US, where you have the company going direct to the end customer instead of using the serv… read more...

Allergan Needs To Stay Focused On The Long Term

via: SeekingAlpha at 2018-06-28 07:49:59:000

Allergan (AGN) wants to strike while the iron's hot and roll out its CoolSculpting technology into international markets as quickly as possible. The objective is to set up international markets like the US, where you have the company going direct to the end customer instead of using the serv… read more...

Allergan Needs To Stay Focused On The Long Term

via: SeekingAlpha at 2018-06-28 07:49:59:000

Allergan (AGN) wants to strike while the iron's hot and roll out its CoolSculpting technology into international markets as quickly as possible. The objective is to set up international markets like the US, where you have the company going direct to the end customer instead of using the serv… read more...

Allergan to Report Second Quarter 2018 Earnings and Host Conference Call and Webcast

via: PR Newswire at 2018-06-26 08:00:00:000

DUBLIN , June 26, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced that it intends to release second quarter 2018 financial results on Thursday, July 26, 2018 , prior to the open of U.S. financial markets. Allergan will host a conference call and webcast at 8:… read more...

Allergan to Report Second Quarter 2018 Earnings and Host Conference Call and Webcast

via: PR Newswire at 2018-06-26 08:00:00:000

DUBLIN , June 26, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced that it intends to release second quarter 2018 financial results on Thursday, July 26, 2018 , prior to the open of U.S. financial markets. Allergan will host a conference call and webcast at 8:… read more...

Top 10 Net Payout Yields - June 2018

via: SeekingAlpha at 2018-06-25 18:51:16:000

This article is a continuation of a monthly series highlighting the top net payout yield ((NPY)) stocks that was started back in June 2012 and explained in August 2012 . The series highlights the best stocks for the upcoming month utilized in part to make investment decisions for the IB As… read more...

Aptinyx: This Recent IPO Should Be On Your Radar

via: SeekingAlpha at 2018-06-22 03:28:46:000

Aptinyx ( APTX ) had a succesful IPO today, offering 6.4 million shares at a price point of $16 per share for gross proceeds of around $102.4 million (not including underwriter over-allotment of 959,999 shares). It looks to me like this one was well-executed, with the stock opening slightly hi… read more...

Aptinyx: This Recent IPO Should Be On Your Radar

via: SeekingAlpha at 2018-06-22 03:28:46:000

Aptinyx ( APTX ) had a succesful IPO today, offering 6.4 million shares at a price point of $16 per share for gross proceeds of around $102.4 million (not including underwriter over-allotment of 959,999 shares). It looks to me like this one was well-executed, with the stock opening slightly hi… read more...

Aptinyx: This Recent IPO Should Be On Your Radar

via: SeekingAlpha at 2018-06-22 03:28:46:000

Aptinyx ( APTX ) had a succesful IPO today, offering 6.4 million shares at a price point of $16 per share for gross proceeds of around $102.4 million (not including underwriter over-allotment of 959,999 shares). It looks to me like this one was well-executed, with the stock opening slightly hi… read more...

Aptinyx: This Recent IPO Should Be On Your Radar

via: SeekingAlpha at 2018-06-22 03:28:46:000

Aptinyx ( APTX ) had a succesful IPO today, offering 6.4 million shares at a price point of $16 per share for gross proceeds of around $102.4 million (not including underwriter over-allotment of 959,999 shares). It looks to me like this one was well-executed, with the stock opening slightly hi… read more...

Evolus: Botox Competitor Poised For Massive Growth

via: SeekingAlpha at 2018-06-20 07:21:48:000

Evolus ( EOLS ) is a medical aesthetics company with the first 900 kDA botulinum toxin (DWP-450) since Botox. The Company has already demonstrated non-inferiority to Botox in several Phase 3 trials. Due to the fact that Evolus is only targeting the aesthetics market (and not the therapeutic… read more...

Synergy Pharmaceuticals: At Last A Glimmer Of Hope?

via: SeekingAlpha at 2018-06-18 11:22:11:000

On June 12 th , Synergy Pharmaceuticals ( SGYP ) held its annual shareholder meeting. While such affairs tend to be straightforward and without incident, this one was very much an oddity. Remarkably, shareholders succeeded in delivering a number of blows to current management, which has been b… read more...

Synergy Pharmaceuticals: At Last A Glimmer Of Hope?

via: SeekingAlpha at 2018-06-18 11:22:11:000

On June 12 th , Synergy Pharmaceuticals ( SGYP ) held its annual shareholder meeting. While such affairs tend to be straightforward and without incident, this one was very much an oddity. Remarkably, shareholders succeeded in delivering a number of blows to current management, which has been b… read more...

Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive

via: SeekingAlpha at 2018-06-15 10:00:00:000

Analysis Focus: WMGI Wright Medical Group N.V. ( WMGI ) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF… read more...

Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive

via: SeekingAlpha at 2018-06-15 10:00:00:000

Analysis Focus: WMGI Wright Medical Group N.V. ( WMGI ) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF… read more...

Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive

via: SeekingAlpha at 2018-06-15 10:00:00:000

Analysis Focus: WMGI Wright Medical Group N.V. ( WMGI ) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF… read more...

Allergan ticks higher as activist investors dial up the pressure for value-boosting action; shares up 2%

via: SeekingAlpha at 2018-06-14 10:21:26:000

Allergan ( AGN +2.2% ) adds to its rally, albeit on below-average volume. Shares have jumped over 13% in a week after activist investor Carl Icahn established a small stake. More news on: Allergan plc, Healthcare stocks news, Stocks on the move, Merger & acquisition news,… read more...

Allergan Continues Active Board Refreshment Process

via: PR Newswire at 2018-06-14 08:00:00:000

DUBLIN , June 14, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced thatThomas C. Freyman will join its Board of Directors effectiveimmediately, as part of the company's ongoing board refreshment process. Mr. Freyman, a former Executive Vice President of Finan… read more...

With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis

via: SeekingAlpha at 2018-06-13 17:32:45:000

Over the last year, Mylan ( MYL ) has faced a difficult generic environment but has managed to offset the pressure with the launch of its generic Copaxone and a strong ex-US business that has helped stabilize the business. The key topics around the stock are now: 1) Neulasta biosimilar appro… read more...

Viking Therapeutics: Hallmark Moment

via: SeekingAlpha at 2018-06-13 10:19:16:000

Hallmark Moments… Writing the perfect greeting card is never easy. Wording needs to be precise. The length so exact. Find all those details you definitely want to include... or leave out. While still managing to strike just the proper tone. Nothing too dark and serious, but also not too ... read more...

Allergan's Bimatoprost ER implant on par with timolol in reducing IOP in late-stage study

via: SeekingAlpha at 2018-06-13 09:14:09:000

Topline data from a Phase 3 clinical trial assessing the ability of Allergan's (NYSE: AGN ) Bimatoprost SR (Sustained-Release), a biodegradable intracameral (into the eye cavity) implant, to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension showe… read more...

Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension

via: PR Newswire at 2018-06-13 08:00:00:000

DUBLIN , June 13, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the release of new topline clinical trial data on Bimatoprost SR, the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressur… read more...

Synergy Pharmaceuticals: Better Days Likely Ahead, But Better Opportunities Elsewhere

via: SeekingAlpha at 2018-06-13 07:56:46:000

Synergy Pharmaceuticals ( SGYP ) is a small, commercial biotechnology company that markets Trulance for chronic idiopathic constipation and constipation associated with irritable bowel syndrome. They are also, very slowly, advancing dolcanatide for ulcerative colitis and colorectal cancer prev… read more...

Allergan's positive data on migraine prevention med atogepant pressures Alder Bio, down 4%

via: SeekingAlpha at 2018-06-11 12:25:14:000

As is so often the case, good news for one biotech is bad for another. Allergan ( AGN +1.1% ) is in the green after reporting positive data on CGRP receptor antagonist atogepant for the prevention of migraine. More news on: Allergan plc, Alder Biopharmaceuticals Inc., Healthcare stocks… read more...

Allergan's positive data on migraine prevention med atogepant pressures Alder Bio, down 4%

via: SeekingAlpha at 2018-06-11 12:25:14:000

As is so often the case, good news for one biotech is bad for another. Allergan ( AGN +1.1% ) is in the green after reporting positive data on CGRP receptor antagonist atogepant for the prevention of migraine. More news on: Allergan plc, Alder Biopharmaceuticals Inc., Healthcare stocks… read more...

The 'Joe Papa' Effect Is Arriving At Valeant

via: SeekingAlpha at 2018-06-11 09:57:29:000

Too often investors spend too much time focusing on graphs, financial metrics, analyst estimates, moving averages, etc. without understanding that there are things in the market that no graph or financial metric can measure. The quality of a management team has a significant effect on how the … read more...

The 'Joe Papa' Effect Is Arriving At Valeant

via: SeekingAlpha at 2018-06-11 09:57:29:000

Too often investors spend too much time focusing on graphs, financial metrics, analyst estimates, moving averages, etc. without understanding that there are things in the market that no graph or financial metric can measure. The quality of a management team has a significant effect on how the … read more...

Allergan's atogepant shows positive effect in Phase 2b/3 migraine study

via: SeekingAlpha at 2018-06-11 08:44:59:000

A Phase 2b/3 clinical trial, CGP-MD-01, assessing Allergan's (NYSE: AGN ) second orally-administered CGRP receptor antagonist atogepant for the prevention of migraine met the primary endpoint across all doses and dose regimens. Patients in the treatment group experienced a statistically si… read more...

Allergan's atogepant shows positive effect in Phase 2b/3 migraine study

via: SeekingAlpha at 2018-06-11 08:44:59:000

A Phase 2b/3 clinical trial, CGP-MD-01, assessing Allergan's (NYSE: AGN ) second orally-administered CGRP receptor antagonist atogepant for the prevention of migraine met the primary endpoint across all doses and dose regimens. Patients in the treatment group experienced a statistically si… read more...

Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial

via: PR Newswire at 2018-06-11 08:00:00:000

DUBLIN , June 11, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced positive results from CGP-MD-01, a Phase 2b /3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant. All active t… read more...

Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial

via: PR Newswire at 2018-06-11 08:00:00:000

DUBLIN , June 11, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced positive results from CGP-MD-01, a Phase 2b /3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant. All active t… read more...

Allergan: Unwelcome Guests?

via: SeekingAlpha at 2018-06-08 12:39:50:000

Allergan ( AGN ) is down 50% from all-time highs back in 2015 so understandably activists are agitating for changes. The time to make those moves was a few years back while now the biopharma needs to execute on the initiatives already set forward by the CEO. A focused and more nimble compa… read more...

Allergan: Unwelcome Guests?

via: SeekingAlpha at 2018-06-08 12:39:50:000

Allergan ( AGN ) is down 50% from all-time highs back in 2015 so understandably activists are agitating for changes. The time to make those moves was a few years back while now the biopharma needs to execute on the initiatives already set forward by the CEO. A focused and more nimble compa… read more...

Allergan: Unwelcome Guests?

via: SeekingAlpha at 2018-06-08 12:39:50:000

Allergan ( AGN ) is down 50% from all-time highs back in 2015 so understandably activists are agitating for changes. The time to make those moves was a few years back while now the biopharma needs to execute on the initiatives already set forward by the CEO. A focused and more nimble compa… read more...

3 Things In Biotech, June 7: The First-Line Lung Fight Heats Up More

via: SeekingAlpha at 2018-06-08 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech," a daily digest dedicate… read more...

3 Things In Biotech, June 7: The First-Line Lung Fight Heats Up More

via: SeekingAlpha at 2018-06-08 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech," a daily digest dedicate… read more...

3 Things In Biotech, June 7: The First-Line Lung Fight Heats Up More

via: SeekingAlpha at 2018-06-08 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech," a daily digest dedicate… read more...

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

via: SeekingAlpha at 2018-06-07 17:22:23:000

Without a saving faith in the future, no one would ever invest at all. To be an investor, you must be a believer in a better tomorrow. - Benjamin Graham In a Seeking Alpha interview back on Sep. 23, 2017, the ingenious market strategist (Robyn Conti) inquired, "What's one idea you feel s… read more...

ElectroCore Readies $65 Million U.S. IPO Plans

via: SeekingAlpha at 2018-06-07 14:48:43:000

Quick Take ElectroCore ( ECOR ) intends to raise $65 million in an IPO of its common stock, according to an S-1/A registration statement . The firm is preparing to commercialize a device that promises to treat various forms of headaches. ECOR has a promising, non-invasive treatment op… read more...

Synergy Pharmaceuticals: CEO Troy Hamilton Is Very Capable - Will He Succeed?

via: SeekingAlpha at 2018-06-07 14:27:18:000

It's very important that shareholders in Synergy Pharmaceuticals understand 2 things in regards to the history of Synergy Pharmaceuticals ( SGYP ). The first one is that most of the mistakes that have occurred in the company trace back to the board of directors (before CEO Troy Hamilton was pa… read more...

Allergan and Actress Shay Mitchell Join Forces to Inspire Women to Know Their Birth Control

via: PR Newswire at 2018-06-07 08:30:00:000

DUBLIN , June 7, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leader in women's healthcare and the maker of Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), today announced the launch of 'B… read more...

Carl Icahn reportedly building small position in Allergan, joining David Tepper

via: CNBC at 2018-06-06 17:00:00:000

No summary available. read more...

Once The Trial Is Over: A Look At Synergy

via: SeekingAlpha at 2018-06-06 13:30:10:000

Congrats, The Drug Is Approved: Now What? Clinical biotech stories often focus on the trial process. Companies move their key candidate through Phase II and Phase III trials, raise money opportunistically while trying to control cash burn, and seek FDA approval. If they gain approva… read more...

PBMs one-up drug makers on drug copay assistance schemes

via: SeekingAlpha at 2018-06-06 11:41:10:000

Reuters reports that U.S. drug prices fell 5.6% in Q1, 3.6% more than a year ago. Sector & Sovereign analyst Richard Evans believes most of the decline is from "copay accumulator" programs instituted by pharmacy benefit managers (PBMs) last quarter that do not allow copay assistance pa… read more...

Your first trade for Wednesday, June 6

via: CNBC at 2018-06-06 09:12:00:000

No summary available. read more...

3 Things In Biotech, June 5: Roche's Very Bad Day

via: SeekingAlpha at 2018-06-06 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

Allergan Responds to Public Shareholder Letter

via: PR Newswire at 2018-06-05 13:42:00:000

DUBLIN , June 5, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today issued the following statement in response to a public shareholder letter: Allergan's board of directors and management welcome input from all our shareholders, and take into account their views. Our board and man… read more...

New analysis affirms risk/benefit profile of Synergy's Trulance in CIC; shares up 5%

via: SeekingAlpha at 2018-06-05 13:02:54:000

A new retrospective risk/benefit analysis from pooled Phase 3 trial data assessing Synergy Pharmaceuticals' ( SGYP +4.7% ) TRULANCE (plecanatide) and Allergan ( AGN +0.8% ) and Ironwood Pharmaceuticals' ( IRWD -0.5% ) LINZESS (linaclotide) in adult patients with chronic idiopathic co… read more...

Tepper says Allergan should split CEO and chairman role and overhaul management

via: CNBC at 2018-06-05 11:54:00:000

No summary available. read more...

Activist investors out of patience with Allergan's performance, urge significant changes; shares up 2%

via: SeekingAlpha at 2018-06-05 11:37:09:000

Allergan ( AGN +1.5% ) is up, albeit on below-average volume, on the heels of the publication of recent communications from long-term institutional investors Appaloosa LP and Senator Investment Group LP to the board. They have lost their patience with management's "half-hearted attempt t… read more...

Allergan Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients and their Caregivers to Hold on to Hope

via: PR Newswire at 2018-06-05 08:00:00:000

DUBLIN , June 5, 2018 /PRNewswire/ --Allergan plc (NYSE:AGN) today announced that, in honor of Alzheimer's & Brain Awareness Month, it is teaming up with notable celebrities Scott Conant , Sean Hayes , Helen Hunt , Soleil Moon Frye , Molly Sims and Trista Sutter to shine… read more...

Allergan Needs Earnings To Be Sustained

via: SeekingAlpha at 2018-06-05 00:52:56:000

I wrote about Allergan ( AGN ) about a month ago and sold the case for writing put spreads on this stock, which basically means adopting a long position but clearly defining one's risk. Although I have never been enamored with this stock, we still are talking about a company which is pumping… read more...

Cramer: Pharmaceutical stocks are underperforming 'like nothing I've ever seen'

via: CNBC at 2018-06-04 11:01:00:000

No summary available. read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

Synergy Pharma: Is Management Really That Bad?

via: SeekingAlpha at 2018-05-31 17:34:10:000

With activist investors at the door and the stock trading below $2, the market has a general presumption that Synergy Pharma ( SGYP ) has bad management. Investors though appear to over look the change that has taken place since Troy Hamilton took over the CEO role in December making a sol… read more...

FDA issues draft guidance aimed at easing regulatory path for generic drugs

via: SeekingAlpha at 2018-05-31 11:27:37:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. announces draft guidance aimed at curtailing behavior by branded drug makers to delay competition from generics. More news on: iShares U.S. Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, Heal… read more...

CoolSculpting® And #WeAllGrow Latina Network Host Discussion On The Perceptions Of Beauty And Body In The Latina Community

via: PR Newswire at 2018-05-30 19:15:00:000

DUBLIN , May 30, 2018 /PRNewswire/ --According to the American Society for Aesthetic Plastic Surgery, Hispanics are a key customer group for in-office medical aesthetic procedures, growing 23.5 percent from 2010 to 2017 2 . This statistic served as a jumping-off point for a conversa… read more...

CoolSculpting® And #WeAllGrow Latina Network Host Discussion On The Perceptions Of Beauty And Body In The Latina Community

via: PR Newswire at 2018-05-30 19:15:00:000

DUBLIN , May 30, 2018 /PRNewswire/ --According to the American Society for Aesthetic Plastic Surgery, Hispanics are a key customer group for in-office medical aesthetic procedures, growing 23.5 percent from 2010 to 2017 2 . This statistic served as a jumping-off point for a conversa… read more...

Allergan to sell multibillion-dollar women's health and infectious disease units after strategic review: Sources

via: CNBC at 2018-05-30 09:40:00:000

No summary available. read more...

Allergan to sell multibillion-dollar women's health and infectious disease units after strategic review: Sources

via: CNBC at 2018-05-30 09:40:00:000

No summary available. read more...

Allergan recalls birth control packs after pills placed out of order

via: SeekingAlpha at 2018-05-29 22:44:18:000

Allergan (NYSE: AGN ) said today it was recalling nearly 170K sample packs of its Taytulla birth control treatment after placebo and active capsules were placed out of order. More news on: Allergan plc, Healthcare stocks news, Read more … read more...

Allergan recalls birth control packs after pills placed out of order

via: SeekingAlpha at 2018-05-29 22:44:18:000

Allergan (NYSE: AGN ) said today it was recalling nearly 170K sample packs of its Taytulla birth control treatment after placebo and active capsules were placed out of order. More news on: Allergan plc, Healthcare stocks news, Read more … read more...

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

via: PR Newswire at 2018-05-29 08:57:00:000

DUBLIN , May 29, 2018 /PRNewswire/ --Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians … read more...

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

via: PR Newswire at 2018-05-29 08:57:00:000

DUBLIN , May 29, 2018 /PRNewswire/ --Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians … read more...

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

via: PR Newswire at 2018-05-29 08:57:00:000

DUBLIN , May 29, 2018 /PRNewswire/ --Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians … read more...

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-29 06:11:49:000

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitzs 13F portfolio on a quarterly basis. It is based on Weitzs regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Wallace Weitzs Weitz Investment Manag… read more...

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-29 06:11:49:000

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitzs 13F portfolio on a quarterly basis. It is based on Weitzs regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Wallace Weitzs Weitz Investment Manag… read more...

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-29 06:11:49:000

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitzs 13F portfolio on a quarterly basis. It is based on Weitzs regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Wallace Weitzs Weitz Investment Manag… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 07:36:01:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins' 13F portfolio on a quarterly basis. It is based on Hawkins' regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Mason Hawkins' Southeastern Asset Management Portfolio ser… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 07:36:01:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins' 13F portfolio on a quarterly basis. It is based on Hawkins' regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Mason Hawkins' Southeastern Asset Management Portfolio ser… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 07:36:01:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins' 13F portfolio on a quarterly basis. It is based on Hawkins' regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Mason Hawkins' Southeastern Asset Management Portfolio ser… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 07:36:01:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins' 13F portfolio on a quarterly basis. It is based on Hawkins' regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Mason Hawkins' Southeastern Asset Management Portfolio ser… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 07:36:01:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins' 13F portfolio on a quarterly basis. It is based on Hawkins' regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Mason Hawkins' Southeastern Asset Management Portfolio ser… read more...

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 07:36:01:000

This article is part of a series that provides an ongoing analysis of the changes made to Mason Hawkins' 13F portfolio on a quarterly basis. It is based on Hawkins' regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Mason Hawkins' Southeastern Asset Management Portfolio ser… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 01:53:29:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins 13F portfolio on a quarterly basis. It is based on Robbins regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Larry Robbins Glenview Capital Manage… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 01:53:29:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins 13F portfolio on a quarterly basis. It is based on Robbins regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Larry Robbins Glenview Capital Manage… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 01:53:29:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins 13F portfolio on a quarterly basis. It is based on Robbins regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Larry Robbins Glenview Capital Manage… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 01:53:29:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins 13F portfolio on a quarterly basis. It is based on Robbins regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Larry Robbins Glenview Capital Manage… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 01:53:29:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins 13F portfolio on a quarterly basis. It is based on Robbins regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Larry Robbins Glenview Capital Manage… read more...

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-25 01:53:29:000

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins 13F portfolio on a quarterly basis. It is based on Robbins regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Larry Robbins Glenview Capital Manage… read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Allergan nabs rights to new antidepressant compound

via: SeekingAlpha at 2018-05-22 09:39:00:000

Allergan ( AGN +0.4% ) exercises its option to acquire drug candidate AGN-241751 from collaboration partner Aptinyx . It plans to develop the NMDA receptor modulator for the treatment of major depressive disorder (MDD). More news on: Allergan plc, Healthcare stocks news, Read… read more...

Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration

via: PR Newswire at 2018-05-22 08:00:00:000

EVANSTON, Ill. , May 22, 2018 /PRNewswire/ --Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an … read more...

Valeant Pharmaceuticals Can Still Go Higher - Cramer's Lightning Round (5/21/18)

via: SeekingAlpha at 2018-05-22 06:46:01:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, May 21. Bullish Calls Royal Caribbean Cruises (RCL): People are worried about rising raw costs and rising competition. Cramer thinks they're wrong. It's a buy. Valeant Pharmaceuticals Internation… read more...

Cramer's lightning round: The bears are wrong about cruise ship stocks

via: CNBC at 2018-05-21 18:51:00:000

No summary available. read more...

Tracking David Tepper's Appaloosa Management Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-21 07:36:19:000

This article is part of a series that provides an ongoing analysis of the changes made to David Teppers 13F portfolio on a quarterly basis. It is based on Appaloosa Managements regulatory 13F Form filed on 05/15/2018. Please visit our Tracking David Teppers Appaloosa… read more...

Esmya Restriction In Europe Could Handcuff Allergan

via: SeekingAlpha at 2018-05-21 01:13:41:000

Last week the European Medicines Agency ("EMA") placed restrictions on Gideon Richter's ( OTC:GEDRY ) Esmya medicine due to potential links to serious liver damage: Hungarian drugmaker Richters Esmya medicine used to treat benign tumors of the womb may have contributed to some ca… read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

MeiraGTx Aims For $86 Million U.S. IPO

via: SeekingAlpha at 2018-05-18 11:44:30:000

Quick Take MeiraGTx ( MGTX ) intends to raise $86.25 million from the sale of its common stock in an IPO, according to a registration statement filed with the SEC. The firm is a clinical stage developer of gene therapies focused on diseases of the eye, salivary gland and central nervou… read more...

Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

via: SeekingAlpha at 2018-05-18 10:09:17:000

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series t… read more...

David Tepper gets US approval to take activist stance on Allergan, if he wants it

via: CNBC at 2018-05-18 09:57:00:000

No summary available. read more...

Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?

via: SeekingAlpha at 2018-05-16 16:58:34:000

Investment Thesis Despite the missteps by Synergy ( SGYP ) management that have taken a toll on the share price for more than a year, it remains there is little doubt that Trulance is a highly differentiated product with a patent extending until March 2032 and it remains only one of three… read more...

FDA OKs first non-opioid treatment for opioid withdrawal

via: SeekingAlpha at 2018-05-16 16:44:42:000

The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...

Allergan to Present at the Bernstein Strategic Decisions Conference

via: PR Newswire at 2018-05-16 16:15:00:000

DUBLIN , May 16, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the Bernstein 34 th Annual Strategic Decisions Conference in New York, NY . The presentation will begin… read more...

Mexico Sees Slim Chances For A New NAFTA Deal; The IEA Expects The Oil Price Spike To Take A Toll (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-05-16 08:53:46:000

Get today's Wall Street Breakfast in podcast form to listen on the go. Today's top stories: In today's top stories: Mexico sees slim chances for a new NAFTA deal; the IEA expects the oil price spike to take a toll; and Amazon fires a new salvo in the supermarket wars. If you are… read more...

Mexico Sees Slim Chances For A New NAFTA Deal; The IEA Expects The Oil Price Spike To Take A Toll (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-05-16 08:53:46:000

Get today's Wall Street Breakfast in podcast form to listen on the go. Today's top stories: In today's top stories: Mexico sees slim chances for a new NAFTA deal; the IEA expects the oil price spike to take a toll; and Amazon fires a new salvo in the supermarket wars. If you are… read more...

Mexico Sees Slim Chances For A New NAFTA Deal; The IEA Expects The Oil Price Spike To Take A Toll (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-05-16 08:53:46:000

Get today's Wall Street Breakfast in podcast form to listen on the go. Today's top stories: In today's top stories: Mexico sees slim chances for a new NAFTA deal; the IEA expects the oil price spike to take a toll; and Amazon fires a new salvo in the supermarket wars. If you are… read more...

Mexico Sees Slim Chances For A New NAFTA Deal; The IEA Expects The Oil Price Spike To Take A Toll (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-05-16 08:53:46:000

Get today's Wall Street Breakfast in podcast form to listen on the go. Today's top stories: In today's top stories: Mexico sees slim chances for a new NAFTA deal; the IEA expects the oil price spike to take a toll; and Amazon fires a new salvo in the supermarket wars. If you are… read more...

Mexico Sees Slim Chances For A New NAFTA Deal; The IEA Expects The Oil Price Spike To Take A Toll (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-05-16 08:53:46:000

Get today's Wall Street Breakfast in podcast form to listen on the go. Today's top stories: In today's top stories: Mexico sees slim chances for a new NAFTA deal; the IEA expects the oil price spike to take a toll; and Amazon fires a new salvo in the supermarket wars. If you are… read more...

Wall Street Breakfast: Clock Ticks Down For New NAFTA

via: SeekingAlpha at 2018-05-16 07:02:07:000

Mexico sees diminishing chances for a new NAFTA deal ahead of tomorrow's deadline - given by U.S. House Speaker Paul Ryan - that would allow for the pact to be approved before a newly elected Congress takes over in January. Further complicating talks are Mexico's presidential elect… read more...

Wall Street Breakfast: Clock Ticks Down For New NAFTA

via: SeekingAlpha at 2018-05-16 07:02:07:000

Mexico sees diminishing chances for a new NAFTA deal ahead of tomorrow's deadline - given by U.S. House Speaker Paul Ryan - that would allow for the pact to be approved before a newly elected Congress takes over in January. Further complicating talks are Mexico's presidential elect… read more...

Wall Street Breakfast: Clock Ticks Down For New NAFTA

via: SeekingAlpha at 2018-05-16 07:02:07:000

Mexico sees diminishing chances for a new NAFTA deal ahead of tomorrow's deadline - given by U.S. House Speaker Paul Ryan - that would allow for the pact to be approved before a newly elected Congress takes over in January. Further complicating talks are Mexico's presidential elect… read more...

Wall Street Breakfast: Clock Ticks Down For New NAFTA

via: SeekingAlpha at 2018-05-16 07:02:07:000

Mexico sees diminishing chances for a new NAFTA deal ahead of tomorrow's deadline - given by U.S. House Speaker Paul Ryan - that would allow for the pact to be approved before a newly elected Congress takes over in January. Further complicating talks are Mexico's presidential elect… read more...

Wall Street Breakfast: Clock Ticks Down For New NAFTA

via: SeekingAlpha at 2018-05-16 07:02:07:000

Mexico sees diminishing chances for a new NAFTA deal ahead of tomorrow's deadline - given by U.S. House Speaker Paul Ryan - that would allow for the pact to be approved before a newly elected Congress takes over in January. Further complicating talks are Mexico's presidential elect… read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

FDA action date today for Evolus' competitor to BOTOX; shares up 5%

via: SeekingAlpha at 2018-05-15 11:37:38:000

Thinly traded micro cap Evolus ( EOLS +4.5% ) is up on modestly higher volume ahead of today's expected FDA decision on its marketing application for prabotulinumtoxinA for the treatment of moderate-to-severe frown lines. More news on: Evolus, Inc., Allergan plc, Healthcare stocks news, … read more...

FDA action date today for Evolus' competitor to BOTOX; shares up 5%

via: SeekingAlpha at 2018-05-15 11:37:38:000

Thinly traded micro cap Evolus ( EOLS +4.5% ) is up on modestly higher volume ahead of today's expected FDA decision on its marketing application for prabotulinumtoxinA for the treatment of moderate-to-severe frown lines. More news on: Evolus, Inc., Allergan plc, Healthcare stocks news, … read more...

FDA action date today for Evolus' competitor to BOTOX; shares up 5%

via: SeekingAlpha at 2018-05-15 11:37:38:000

Thinly traded micro cap Evolus ( EOLS +4.5% ) is up on modestly higher volume ahead of today's expected FDA decision on its marketing application for prabotulinumtoxinA for the treatment of moderate-to-severe frown lines. More news on: Evolus, Inc., Allergan plc, Healthcare stocks news, … read more...

FDA action date today for Evolus' competitor to BOTOX; shares up 5%

via: SeekingAlpha at 2018-05-15 11:37:38:000

Thinly traded micro cap Evolus ( EOLS +4.5% ) is up on modestly higher volume ahead of today's expected FDA decision on its marketing application for prabotulinumtoxinA for the treatment of moderate-to-severe frown lines. More news on: Evolus, Inc., Allergan plc, Healthcare stocks news, … read more...

FDA action date today for Evolus' competitor to BOTOX; shares up 5%

via: SeekingAlpha at 2018-05-15 11:37:38:000

Thinly traded micro cap Evolus ( EOLS +4.5% ) is up on modestly higher volume ahead of today's expected FDA decision on its marketing application for prabotulinumtoxinA for the treatment of moderate-to-severe frown lines. More news on: Evolus, Inc., Allergan plc, Healthcare stocks news, … read more...

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

via: SeekingAlpha at 2018-05-15 10:33:51:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

via: SeekingAlpha at 2018-05-15 10:33:51:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

via: SeekingAlpha at 2018-05-15 10:33:51:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

via: SeekingAlpha at 2018-05-15 10:33:51:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

via: SeekingAlpha at 2018-05-15 10:33:51:000

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...

Evolus: Is The Botox Knock Off Finally Here?

via: SeekingAlpha at 2018-05-14 14:59:30:000

Source: pulsenews.co.kr Shares of Evolus ( EOLS ) spiked Monday ahead of a key U.S. Food and Drug Administration ("FDA") decision pursuant to PrabotulinumtoxinA (DWP-450), an injectable 900 kDa botulinum toxin type A complex designed to address the needs of the facial aesthetics market. Th… read more...

Will Mullets Bail Out Allergan?

via: SeekingAlpha at 2018-05-14 10:04:43:000

Allergan CEO Brent Saunders. Source: Business Insider I have been bearish on Allergan ( AGN ) since the second half of 2017. I thought the company's Q2 2017 revenue growth in the high single-digits was driven more by acquisitions than via organic sales. After the company reported Q1 2018 r… read more...

Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President's Healthcare Plans

via: SeekingAlpha at 2018-05-14 10:00:00:000

Analysis focus: OMER Omeros (NASDAQ: OMER ) is moving towards a rolling BLA submission for OMS721. On this good news, and despite tepid Q1 results, investors are becoming increasingly bullish the stock, as seen by its sudden 23% spike on the news of the BLA submission. OMS721 is in tri… read more...

Johnson & Johnson: Waiting On The Wave

via: SeekingAlpha at 2018-05-11 15:16:04:000

Watching an 80-foot wave break at Nazar, Portugal. (via YouTube ). A "Tidal Wave" Of Opioids Lawsuits Last August, the Financial times warned that a "tidal wave" of opioid-related lawsuits was headed for Johnson & Johnson ( JNJ ) and some of its competitors (paywalled here )… read more...

Teva's Luck Continues To Run Out

via: SeekingAlpha at 2018-02-12 15:14:57:000

Teva ( TEVA ) has been performing poorly over the last few years as its generics business has been declining in sales. It managed to beat its fourth quarter earnings, but stated that 2018 will be quite rocky. The lower guide along with many other problems that Teva currently faces continue… read more...

Teva's Luck Continues To Run Out

via: SeekingAlpha at 2018-02-12 15:14:57:000

Teva ( TEVA ) has been performing poorly over the last few years as its generics business has been declining in sales. It managed to beat its fourth quarter earnings, but stated that 2018 will be quite rocky. The lower guide along with many other problems that Teva currently faces continue… read more...

Teva Pharmaceuticals Could Bounce Back To $20

via: SeekingAlpha at 2018-02-12 14:12:32:000

Just when it looked as though Teva Pharmaceuticals ( TEVA ) would settle at $10 in November 2017, the stock barely managed to hold the $11 mark and went on to more than double from there. But fourth-quarter results gave its shareholders a dose of reality. Revenue is in free-fall and the ge… read more...

Teva Pharmaceuticals Could Bounce Back To $20

via: SeekingAlpha at 2018-02-12 14:12:32:000

Just when it looked as though Teva Pharmaceuticals ( TEVA ) would settle at $10 in November 2017, the stock barely managed to hold the $11 mark and went on to more than double from there. But fourth-quarter results gave its shareholders a dose of reality. Revenue is in free-fall and the ge… read more...

Wall Street Breakfast: Infrastructure Details Coming Today

via: SeekingAlpha at 2018-02-12 07:07:40:000

The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...

Wall Street Breakfast: Infrastructure Details Coming Today

via: SeekingAlpha at 2018-02-12 07:07:40:000

The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

Allergan: Be Brave And Buy This Underappreciated Stock

via: SeekingAlpha at 2018-02-10 03:12:55:000

On February 6, 2018, Allergan (AGN) reported strong Q4 2017 results , thanks to a solid performance of the key aesthetics growth drivers and an excellent Opex management. With the stock trading below 11x on NTM P/E, I think that the current valuation of Allergan is extremely attractive and … read more...

Allergan: Be Brave And Buy This Underappreciated Stock

via: SeekingAlpha at 2018-02-10 03:12:55:000

On February 6, 2018, Allergan (AGN) reported strong Q4 2017 results , thanks to a solid performance of the key aesthetics growth drivers and an excellent Opex management. With the stock trading below 11x on NTM P/E, I think that the current valuation of Allergan is extremely attractive and … read more...

Allergan: Be Brave And Buy This Underappreciated Stock

via: SeekingAlpha at 2018-02-10 03:12:55:000

On February 6, 2018, Allergan (AGN) reported strong Q4 2017 results , thanks to a solid performance of the key aesthetics growth drivers and an excellent Opex management. With the stock trading below 11x on NTM P/E, I think that the current valuation of Allergan is extremely attractive and … read more...

Allergan: Be Brave And Buy This Underappreciated Stock

via: SeekingAlpha at 2018-02-10 03:12:55:000

On February 6, 2018, Allergan (AGN) reported strong Q4 2017 results , thanks to a solid performance of the key aesthetics growth drivers and an excellent Opex management. With the stock trading below 11x on NTM P/E, I think that the current valuation of Allergan is extremely attractive and … read more...

Allergan: Right On Schedule

via: SeekingAlpha at 2018-02-09 20:19:51:000

Despite fears that Allergan ( AGN ) will suddenly lose a ton of key drugs off patent, the biopharma continues delivering solid results. The maker of Botox and other cosmetic products has a stronger revenue stream and pipeline than the extrapolated fears appear to understand that have sent … read more...

Allergan: Right On Schedule

via: SeekingAlpha at 2018-02-09 20:19:51:000

Despite fears that Allergan ( AGN ) will suddenly lose a ton of key drugs off patent, the biopharma continues delivering solid results. The maker of Botox and other cosmetic products has a stronger revenue stream and pipeline than the extrapolated fears appear to understand that have sent … read more...

Allergan: Right On Schedule

via: SeekingAlpha at 2018-02-09 20:19:51:000

Despite fears that Allergan ( AGN ) will suddenly lose a ton of key drugs off patent, the biopharma continues delivering solid results. The maker of Botox and other cosmetic products has a stronger revenue stream and pipeline than the extrapolated fears appear to understand that have sent … read more...

Allergan: Right On Schedule

via: SeekingAlpha at 2018-02-09 20:19:51:000

Despite fears that Allergan ( AGN ) will suddenly lose a ton of key drugs off patent, the biopharma continues delivering solid results. The maker of Botox and other cosmetic products has a stronger revenue stream and pipeline than the extrapolated fears appear to understand that have sent … read more...

T2 Biosystems Is Transforming The Treatment Of Sepsis

via: SeekingAlpha at 2018-02-09 14:25:30:000

Introduction: T2 Biosystems ( TTOO ) is a healthcare diagnostics company headquartered in Lexington, Massachusetts. The company, led by CEO John McDonough, is focused on addressing a variety of unmet needs in healthcare, primarily through their pipeline of solutions for Sepsis, which is… read more...

T2 Biosystems Is Transforming The Treatment Of Sepsis

via: SeekingAlpha at 2018-02-09 14:25:30:000

Introduction: T2 Biosystems ( TTOO ) is a healthcare diagnostics company headquartered in Lexington, Massachusetts. The company, led by CEO John McDonough, is focused on addressing a variety of unmet needs in healthcare, primarily through their pipeline of solutions for Sepsis, which is… read more...

T2 Biosystems Is Transforming The Treatment Of Sepsis

via: SeekingAlpha at 2018-02-09 14:25:30:000

Introduction: T2 Biosystems ( TTOO ) is a healthcare diagnostics company headquartered in Lexington, Massachusetts. The company, led by CEO John McDonough, is focused on addressing a variety of unmet needs in healthcare, primarily through their pipeline of solutions for Sepsis, which is… read more...

T2 Biosystems Is Transforming The Treatment Of Sepsis

via: SeekingAlpha at 2018-02-09 14:25:30:000

Introduction: T2 Biosystems ( TTOO ) is a healthcare diagnostics company headquartered in Lexington, Massachusetts. The company, led by CEO John McDonough, is focused on addressing a variety of unmet needs in healthcare, primarily through their pipeline of solutions for Sepsis, which is… read more...

T2 Biosystems Is Transforming The Treatment Of Sepsis

via: SeekingAlpha at 2018-02-09 14:25:30:000

Introduction: T2 Biosystems ( TTOO ) is a healthcare diagnostics company headquartered in Lexington, Massachusetts. The company, led by CEO John McDonough, is focused on addressing a variety of unmet needs in healthcare, primarily through their pipeline of solutions for Sepsis, which is… read more...

Allergan declares $0.72 dividend

via: SeekingAlpha at 2018-02-09 08:52:12:000

Allergan (NYSE: AGN ) declares $0.72/share quarterly dividend , 2.9% increase from prior dividend of $0.70. More news on: Allergan plc, Dividend news, Read more … read more...

Allergan declares $0.72 dividend

via: SeekingAlpha at 2018-02-09 08:52:12:000

Allergan (NYSE: AGN ) declares $0.72/share quarterly dividend , 2.9% increase from prior dividend of $0.70. More news on: Allergan plc, Dividend news, Read more … read more...

Allergan declares $0.72 dividend

via: SeekingAlpha at 2018-02-09 08:52:12:000

Allergan (NYSE: AGN ) declares $0.72/share quarterly dividend , 2.9% increase from prior dividend of $0.70. More news on: Allergan plc, Dividend news, Read more … read more...

Allergan declares $0.72 dividend

via: SeekingAlpha at 2018-02-09 08:52:12:000

Allergan (NYSE: AGN ) declares $0.72/share quarterly dividend , 2.9% increase from prior dividend of $0.70. More news on: Allergan plc, Dividend news, Read more … read more...

Allergan declares $0.72 dividend

via: SeekingAlpha at 2018-02-09 08:52:12:000

Allergan (NYSE: AGN ) declares $0.72/share quarterly dividend , 2.9% increase from prior dividend of $0.70. More news on: Allergan plc, Dividend news, Read more … read more...

Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates

via: PR Newswire at 2018-02-09 08:00:00:000

DUBLIN , Feb. 9, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28, 2018 to shareholders of record at the close of busi… read more...

Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates

via: PR Newswire at 2018-02-09 08:00:00:000

DUBLIN , Feb. 9, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28, 2018 to shareholders of record at the close of busi… read more...

Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates

via: PR Newswire at 2018-02-09 08:00:00:000

DUBLIN , Feb. 9, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28, 2018 to shareholders of record at the close of busi… read more...

Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates

via: PR Newswire at 2018-02-09 08:00:00:000

DUBLIN , Feb. 9, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28, 2018 to shareholders of record at the close of busi… read more...

Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates

via: PR Newswire at 2018-02-09 08:00:00:000

DUBLIN , Feb. 9, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28, 2018 to shareholders of record at the close of busi… read more...

Investment Ideas: Beating The Market By Focusing On Cash Distributions

via: SeekingAlpha at 2018-02-07 14:57:07:000

Cash distributions can have a big impact on shareholder returns over the long term. Many investors are closely familiar with dividends, but there is much more to cash distributions than dividend payments alone. Shareholder yield is a metric that considers not only dividend payments, but also c… read more...

Investment Ideas: Beating The Market By Focusing On Cash Distributions

via: SeekingAlpha at 2018-02-07 14:57:07:000

Cash distributions can have a big impact on shareholder returns over the long term. Many investors are closely familiar with dividends, but there is much more to cash distributions than dividend payments alone. Shareholder yield is a metric that considers not only dividend payments, but also c… read more...

Investment Ideas: Beating The Market By Focusing On Cash Distributions

via: SeekingAlpha at 2018-02-07 14:57:07:000

Cash distributions can have a big impact on shareholder returns over the long term. Many investors are closely familiar with dividends, but there is much more to cash distributions than dividend payments alone. Shareholder yield is a metric that considers not only dividend payments, but also c… read more...

JP Morgan reveals top pharma picks after earnings

via: CNBC at 2018-02-07 14:55:00:000

No summary available. read more...

JP Morgan reveals top pharma picks after earnings

via: CNBC at 2018-02-07 14:55:00:000

No summary available. read more...

JP Morgan reveals top pharma picks after earnings

via: CNBC at 2018-02-07 14:55:00:000

No summary available. read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 6, 2018

via: SeekingAlpha at 2018-02-07 12:19:25:000

Market and sector outlook: The broad U.S. market ( SPY ) and the biotech sector ( IBB ) rebounded today after hitting 200-DMA, a key support level as we mentioned in the yesterdays update. VIX reversed course. The volatility is classic for the late stage of an economic cycle. S&am… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 6, 2018

via: SeekingAlpha at 2018-02-07 12:19:25:000

Market and sector outlook: The broad U.S. market ( SPY ) and the biotech sector ( IBB ) rebounded today after hitting 200-DMA, a key support level as we mentioned in the yesterdays update. VIX reversed course. The volatility is classic for the late stage of an economic cycle. S&am… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 6, 2018

via: SeekingAlpha at 2018-02-07 12:19:25:000

Market and sector outlook: The broad U.S. market ( SPY ) and the biotech sector ( IBB ) rebounded today after hitting 200-DMA, a key support level as we mentioned in the yesterdays update. VIX reversed course. The volatility is classic for the late stage of an economic cycle. S&am… read more...

Another February Biotech Catalyst To Watch

via: SeekingAlpha at 2018-02-07 09:34:07:000

At the end of January, I published the February entry of my monthly biotech catalysts preview. While the three companies discussed, Dynavax Technologies ( DVAX ), Novavax ( NVAX ), and Puma Biotechnology ( PBYI ) all have interesting catalysts ahead of them this month, they are not alone. Ev… read more...

Another February Biotech Catalyst To Watch

via: SeekingAlpha at 2018-02-07 09:34:07:000

At the end of January, I published the February entry of my monthly biotech catalysts preview. While the three companies discussed, Dynavax Technologies ( DVAX ), Novavax ( NVAX ), and Puma Biotechnology ( PBYI ) all have interesting catalysts ahead of them this month, they are not alone. Ev… read more...

Another February Biotech Catalyst To Watch

via: SeekingAlpha at 2018-02-07 09:34:07:000

At the end of January, I published the February entry of my monthly biotech catalysts preview. While the three companies discussed, Dynavax Technologies ( DVAX ), Novavax ( NVAX ), and Puma Biotechnology ( PBYI ) all have interesting catalysts ahead of them this month, they are not alone. Ev… read more...

Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results

via: SeekingAlpha at 2018-02-07 08:00:00:000

Analysis of top Seeking Alpha coverage: Nabriva Today we will discuss Nabriva Therapeutics ( NBRV ), which saw a sharp pullback in after-hours trading on Monday. NBRV shares were down more than 9% in after-hours trading on Monday. The sharp pullback was mainly due to the announcemen… read more...

3 Things In Biotech You Should Learn Today: February 6, 2018

via: SeekingAlpha at 2018-02-07 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 6, 2018

via: SeekingAlpha at 2018-02-07 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results

via: SeekingAlpha at 2018-02-07 08:00:00:000

Analysis of top Seeking Alpha coverage: Nabriva Today we will discuss Nabriva Therapeutics ( NBRV ), which saw a sharp pullback in after-hours trading on Monday. NBRV shares were down more than 9% in after-hours trading on Monday. The sharp pullback was mainly due to the announcemen… read more...

3 Things In Biotech You Should Learn Today: February 6, 2018

via: SeekingAlpha at 2018-02-07 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results

via: SeekingAlpha at 2018-02-07 08:00:00:000

Analysis of top Seeking Alpha coverage: Nabriva Today we will discuss Nabriva Therapeutics ( NBRV ), which saw a sharp pullback in after-hours trading on Monday. NBRV shares were down more than 9% in after-hours trading on Monday. The sharp pullback was mainly due to the announcemen… read more...

Wall Street Breakfast: Volatility Plagues The Markets

via: SeekingAlpha at 2018-02-07 07:00:52:000

U.S. stock index futures dropped deep into the red again overnight, pulling back from the roller coaster ride in the previous session that saw the DJIA close up 567 points following two major selloffs. Some of the reasons given for the sharp swings include fears over interest rates… read more...

Wall Street Breakfast: Volatility Plagues The Markets

via: SeekingAlpha at 2018-02-07 07:00:52:000

U.S. stock index futures dropped deep into the red again overnight, pulling back from the roller coaster ride in the previous session that saw the DJIA close up 567 points following two major selloffs. Some of the reasons given for the sharp swings include fears over interest rates… read more...

Wall Street Breakfast: Volatility Plagues The Markets

via: SeekingAlpha at 2018-02-07 07:00:52:000

U.S. stock index futures dropped deep into the red again overnight, pulling back from the roller coaster ride in the previous session that saw the DJIA close up 567 points following two major selloffs. Some of the reasons given for the sharp swings include fears over interest rates… read more...

Allergan: Still No Triggers, Soft 2018 Ahead

via: SeekingAlpha at 2018-02-06 21:47:26:000

Allergan ( AGN ) reported a strong end to 2017, although this is overshadowed by a soft guidance for 2018. In December I concluded that I was cautious on Allergan, even as shares have been lagging a great deal already, in an article named: "I am allergic to aggressive practices." Despi… read more...

Allergan: Still No Triggers, Soft 2018 Ahead

via: SeekingAlpha at 2018-02-06 21:47:26:000

Allergan ( AGN ) reported a strong end to 2017, although this is overshadowed by a soft guidance for 2018. In December I concluded that I was cautious on Allergan, even as shares have been lagging a great deal already, in an article named: "I am allergic to aggressive practices." Despi… read more...

Allergan Plc (AGN) Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-06 21:35:11:000

Allergan Plc (AGN) Q4 2017 Earnings Call February 06, 2018 8:30 am ET Executives Daphne Karydas - Allergan Plc Brenton L. Saunders - Allergan Plc William J. Meury - Allergan Plc C. David Nicholson - Allergan Plc Maria Teresa Hilado - Allergan Plc Analysts Seamus Fernand… read more...

Allergan Plc (AGN) Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-06 21:35:11:000

Allergan Plc (AGN) Q4 2017 Earnings Call February 06, 2018 8:30 am ET Executives Daphne Karydas - Allergan Plc Brenton L. Saunders - Allergan Plc William J. Meury - Allergan Plc C. David Nicholson - Allergan Plc Maria Teresa Hilado - Allergan Plc Analysts Seamus Fernand… read more...

Allergan plc 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-06 14:19:29:000

The following slide deck was published by Allergan plc in conjunction with their 2017 Q4 earnings Read more … read more...

Biotech Forum Daily Digest For February 3rd

via: SeekingAlpha at 2018-02-03 22:05:55:000

M oral indignation is jealousy with a halo . H.G. Wells The Dow and the rest of the market just had their worst weekly performance in two years. The Dow dropped 4.1% on the week. Biotech followed the rest of the market down as investors went into 'risk off' mode. The main … read more...

Allergan completes restructuring, sees $500M in China sales by 2022

via: SeekingAlpha at 2018-02-02 15:25:16:000

Reuters reports that Allergan ( AGN -3.1% ) has almost completed its restructuring under which 1,000 jobs were eliminated, 800 in the U.S. More news on: Allergan plc, Healthcare stocks news, Read more … read more...

Allergan completes restructuring, sees $500M in China sales by 2022

via: SeekingAlpha at 2018-02-02 15:25:16:000

Reuters reports that Allergan ( AGN -3.1% ) has almost completed its restructuring under which 1,000 jobs were eliminated, 800 in the U.S. More news on: Allergan plc, Healthcare stocks news, Read more … read more...

Allergan completes restructuring, sees $500M in China sales by 2022

via: SeekingAlpha at 2018-02-02 15:25:16:000

Reuters reports that Allergan ( AGN -3.1% ) has almost completed its restructuring under which 1,000 jobs were eliminated, 800 in the U.S. More news on: Allergan plc, Healthcare stocks news, Read more … read more...

Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept

via: SeekingAlpha at 2018-02-02 12:03:00:000

We are kicking off our "Theme of the Month" series today, covering a themed topic for every month. For February, it's NASH (non-alcoholic steatohepatitis). In other months, we will take up diseases, conferences, or anything else that needs deep focus. For more details about the NASH schedule, … read more...

Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept

via: SeekingAlpha at 2018-02-02 12:03:00:000

We are kicking off our "Theme of the Month" series today, covering a themed topic for every month. For February, it's NASH (non-alcoholic steatohepatitis). In other months, we will take up diseases, conferences, or anything else that needs deep focus. For more details about the NASH schedule, … read more...

Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept

via: SeekingAlpha at 2018-02-02 12:03:00:000

We are kicking off our "Theme of the Month" series today, covering a themed topic for every month. For February, it's NASH (non-alcoholic steatohepatitis). In other months, we will take up diseases, conferences, or anything else that needs deep focus. For more details about the NASH schedule, … read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

via: PR Newswire at 2018-02-01 16:31:00:000

DUBLIN , Feb. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ (ceftazid… read more...

FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

via: PR Newswire at 2018-02-01 16:31:00:000

DUBLIN , Feb. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ (ceftazid… read more...

FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

via: PR Newswire at 2018-02-01 16:31:00:000

DUBLIN , Feb. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ (ceftazid… read more...

RiverPark Focused Value Fund Q4 2017 Performance Summary

via: SeekingAlpha at 2018-02-01 11:18:57:000

Read more … read more...

RiverPark Focused Value Fund Q4 2017 Performance Summary

via: SeekingAlpha at 2018-02-01 11:18:57:000

Read more … read more...

RiverPark Focused Value Fund Q4 2017 Performance Summary

via: SeekingAlpha at 2018-02-01 11:18:57:000

Read more … read more...

Allergan to Present at The Leerink Partners 7th Annual Global Healthcare Conference

via: PR Newswire at 2018-01-31 16:15:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury and Chief Research and Development Officer David Nicholson will present at the Leerink Partners 7 th Annual Gl… read more...

Allergan to Present at The Leerink Partners 7th Annual Global Healthcare Conference

via: PR Newswire at 2018-01-31 16:15:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury and Chief Research and Development Officer David Nicholson will present at the Leerink Partners 7 th Annual Gl… read more...

Allergan to Present at The Leerink Partners 7th Annual Global Healthcare Conference

via: PR Newswire at 2018-01-31 16:15:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury and Chief Research and Development Officer David Nicholson will present at the Leerink Partners 7 th Annual Gl… read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Allergan Introduces "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® and Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Golfer Ian Poulter

via: PR Newswire at 2018-01-31 07:31:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today launches a new multi-channel direct-to-consumer campaign for CoolSculpting, titled "Not Cool vs. Cool," which includes a national traditional and digital media effort and two new brand ambassadors: figure skating supers… read more...

Allergan Introduces "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® and Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Golfer Ian Poulter

via: PR Newswire at 2018-01-31 07:31:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today launches a new multi-channel direct-to-consumer campaign for CoolSculpting, titled "Not Cool vs. Cool," which includes a national traditional and digital media effort and two new brand ambassadors: figure skating supers… read more...

Allergan Introduces "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® and Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Golfer Ian Poulter

via: PR Newswire at 2018-01-31 07:31:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today launches a new multi-channel direct-to-consumer campaign for CoolSculpting, titled "Not Cool vs. Cool," which includes a national traditional and digital media effort and two new brand ambassadors: figure skating supers… read more...

Rising health-care costs a 'huge threat' to US economy: Cleveland Clinic's Toby Cosgrove

via: CNBC at 2018-01-30 16:02:00:000

No summary available. read more...

Rising health-care costs a 'huge threat' to US economy: Cleveland Clinic's Toby Cosgrove

via: CNBC at 2018-01-30 16:02:00:000

No summary available. read more...

Rising health-care costs a 'huge threat' to US economy: Cleveland Clinic's Toby Cosgrove

via: CNBC at 2018-01-30 16:02:00:000

No summary available. read more...

Height weighs in on Amazon/Berkshire/JPMorgan healthcare venture

via: SeekingAlpha at 2018-01-30 10:05:07:000

Height Securities' Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon, Berkshire Hathaway and JPMorgan's planned venture into healthcare. The margins are too thin and setting up a care network is expensive and difficult. More news on: Express Scripts, Inc., … read more...

Height weighs in on Amazon/Berkshire/JPMorgan healthcare venture

via: SeekingAlpha at 2018-01-30 10:05:07:000

Height Securities' Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon, Berkshire Hathaway and JPMorgan's planned venture into healthcare. The margins are too thin and setting up a care network is expensive and difficult. More news on: Express Scripts, Inc., … read more...

Height weighs in on Amazon/Berkshire/JPMorgan healthcare venture

via: SeekingAlpha at 2018-01-30 10:05:07:000

Height Securities' Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon, Berkshire Hathaway and JPMorgan's planned venture into healthcare. The margins are too thin and setting up a care network is expensive and difficult. More news on: Express Scripts, Inc., … read more...

Pershing Square (Bill Ackman) London Investor Meeting January 29, 2018

via: SeekingAlpha at 2018-01-30 04:27:00:000

Read more … read more...

Pershing Square (Bill Ackman) London Investor Meeting January 29, 2018

via: SeekingAlpha at 2018-01-30 04:27:00:000

Read more … read more...

Pershing Square (Bill Ackman) London Investor Meeting January 29, 2018

via: SeekingAlpha at 2018-01-30 04:27:00:000

Read more … read more...

United Therapeutics Could See Tyvaso Pressure As MannKind Submits IND For Inhaled Version Of Treprostinil

via: SeekingAlpha at 2018-01-30 02:07:21:000

United Therapeutics ( UTHR ) may find itself forced to the negotiation table at some point in the not too distant future because there is a new entrant being considered in the inhaled version of Treprostinil. United Therapeutics markets its own inhaled version under the trade name Tyvaso. Ma… read more...

United Therapeutics Could See Tyvaso Pressure As MannKind Submits IND For Inhaled Version Of Treprostinil

via: SeekingAlpha at 2018-01-30 02:07:21:000

United Therapeutics ( UTHR ) may find itself forced to the negotiation table at some point in the not too distant future because there is a new entrant being considered in the inhaled version of Treprostinil. United Therapeutics markets its own inhaled version under the trade name Tyvaso. Ma… read more...

United Therapeutics Could See Tyvaso Pressure As MannKind Submits IND For Inhaled Version Of Treprostinil

via: SeekingAlpha at 2018-01-30 02:07:21:000

United Therapeutics ( UTHR ) may find itself forced to the negotiation table at some point in the not too distant future because there is a new entrant being considered in the inhaled version of Treprostinil. United Therapeutics markets its own inhaled version under the trade name Tyvaso. Ma… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-29 08:18:26:000

T2 Biosystems (NASDAQ: TTOO ) initiated with Neutral rating and $5.20 (flat) price target at Goldman Sachs. More news on: T2 Biosystems, Qiagen N.V., Myriad Genetics, Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-29 08:18:26:000

T2 Biosystems (NASDAQ: TTOO ) initiated with Neutral rating and $5.20 (flat) price target at Goldman Sachs. More news on: T2 Biosystems, Qiagen N.V., Myriad Genetics, Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-29 08:18:26:000

T2 Biosystems (NASDAQ: TTOO ) initiated with Neutral rating and $5.20 (flat) price target at Goldman Sachs. More news on: T2 Biosystems, Qiagen N.V., Myriad Genetics, Inc., Healthcare stocks news, Read more … read more...

Teva: Where Did The Bears Go?

via: SeekingAlpha at 2018-01-28 09:13:33:000

Don't call it a comeback (Image source: MemeCrunch ) Authors Note : I have been so consumed by work and pursuing other ventures (as well as finishing a fiction novel), that it has left me little time to comment and share newer investment ideas/opportunities. I fear that my invest… read more...

Teva: Where Did The Bears Go?

via: SeekingAlpha at 2018-01-28 09:13:33:000

Don't call it a comeback (Image source: MemeCrunch ) Authors Note : I have been so consumed by work and pursuing other ventures (as well as finishing a fiction novel), that it has left me little time to comment and share newer investment ideas/opportunities. I fear that my invest… read more...

Teva: Where Did The Bears Go?

via: SeekingAlpha at 2018-01-28 09:13:33:000

Don't call it a comeback (Image source: MemeCrunch ) Authors Note : I have been so consumed by work and pursuing other ventures (as well as finishing a fiction novel), that it has left me little time to comment and share newer investment ideas/opportunities. I fear that my invest… read more...

Clearbridge Value Trust Q4 2017 Product Commentary

via: SeekingAlpha at 2018-01-28 07:52:46:000

Read more … read more...

Clearbridge Value Trust Q4 2017 Product Commentary

via: SeekingAlpha at 2018-01-28 07:52:46:000

Read more … read more...

Clearbridge Value Trust Q4 2017 Product Commentary

via: SeekingAlpha at 2018-01-28 07:52:46:000

Read more … read more...

Clearbridge Value Trust Q4 2017 Product Commentary

via: SeekingAlpha at 2018-01-28 07:52:46:000

Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Synergy Gets A Win, But The Real Test Still Lies Ahead

via: SeekingAlpha at 2018-01-26 05:47:44:000

Synergy Pharmaceuticals ( SGYP ) got a dose of good news early on January 25 th when the FDA approved its constipation drug Trulance for the treatment of irritable bowel syndrome with constipation, or IBS-C. Trulance had already been approved for the treatment of chronic idiopathic constipa… read more...

Synergy Gets A Win, But The Real Test Still Lies Ahead

via: SeekingAlpha at 2018-01-26 05:47:44:000

Synergy Pharmaceuticals ( SGYP ) got a dose of good news early on January 25 th when the FDA approved its constipation drug Trulance for the treatment of irritable bowel syndrome with constipation, or IBS-C. Trulance had already been approved for the treatment of chronic idiopathic constipa… read more...

Synergy Gets A Win, But The Real Test Still Lies Ahead

via: SeekingAlpha at 2018-01-26 05:47:44:000

Synergy Pharmaceuticals ( SGYP ) got a dose of good news early on January 25 th when the FDA approved its constipation drug Trulance for the treatment of irritable bowel syndrome with constipation, or IBS-C. Trulance had already been approved for the treatment of chronic idiopathic constipa… read more...

Synergy Gets A Win, But The Real Test Still Lies Ahead

via: SeekingAlpha at 2018-01-26 05:47:44:000

Synergy Pharmaceuticals ( SGYP ) got a dose of good news early on January 25 th when the FDA approved its constipation drug Trulance for the treatment of irritable bowel syndrome with constipation, or IBS-C. Trulance had already been approved for the treatment of chronic idiopathic constipa… read more...

Synergy Gets A Win, But The Real Test Still Lies Ahead

via: SeekingAlpha at 2018-01-26 05:47:44:000

Synergy Pharmaceuticals ( SGYP ) got a dose of good news early on January 25 th when the FDA approved its constipation drug Trulance for the treatment of irritable bowel syndrome with constipation, or IBS-C. Trulance had already been approved for the treatment of chronic idiopathic constipa… read more...

Synergy Gets A Win, But The Real Test Still Lies Ahead

via: SeekingAlpha at 2018-01-26 05:47:44:000

Synergy Pharmaceuticals ( SGYP ) got a dose of good news early on January 25 th when the FDA approved its constipation drug Trulance for the treatment of irritable bowel syndrome with constipation, or IBS-C. Trulance had already been approved for the treatment of chronic idiopathic constipa… read more...

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

via: SeekingAlpha at 2018-01-25 14:10:20:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This… read more...

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

via: SeekingAlpha at 2018-01-25 14:10:20:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This… read more...

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

via: SeekingAlpha at 2018-01-25 14:10:20:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This… read more...

Weitz Value Fund Q4 2017 Quarterly Commentary

via: SeekingAlpha at 2018-01-24 08:04:11:000

Read more … read more...

FDA OKs two new Perrigo generics

via: SeekingAlpha at 2018-01-24 08:03:58:000

The FDA approves Perrigo's (NASDAQ: PRGO ) generic version of Allergan's (NYSE: AGN ) ESTRACE Cream (estradiol vaginal cream) for the treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause. According to IQVIA, the U.S. market is ~$457M. More news on: Pe… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-23 08:46:56:000

Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...

Top 10 Net Payout Yields For January 2018

via: SeekingAlpha at 2018-01-21 19:32:42:000

This article is a continuation of a monthly series highlighting the top net payout yield (NPY) stocks that was started back in June 2012 and explained in August 2012 . The series highlights the best stocks for the upcoming month utilized in part to make investment decisions for the IB Asse… read more...

Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update

via: SeekingAlpha at 2018-01-20 07:59:00:000

Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...

EC OKs Amgen's Avastin biosimilar

via: SeekingAlpha at 2018-01-18 16:26:26:000

As expected, the European Commission (EC) approves Amgen (NASDAQ: AMGN ) and development partner Allergan's (NYSE: AGN ) MVASI, a biosimilar of Roche's ( OTCQX:RHHBY ) Avastin. The FDA approved it in September 2017. More news on: Amgen Inc., Allergan plc, Roche Holding Ltd ADR, Healthcar… read more...

European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

via: PR Newswire at 2018-01-18 16:00:00:000

THOUSAND OAKS, Calif. , Jan. 18, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approve… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2018-02-27 2018-03-28 2018-02-28 2018-02-09 0.72 Dividend income
2017-11-16 2017-12-15 2017-11-17 2017-10-27 0.7 FI Dividend income
2017-08-16 2017-09-15 2017-08-18 2017-08-02 0.7 Dividend income
2017-05-16 2017-06-15 2017-05-18 2017-05-05 0.7 Dividend income
2017-02-24 2017-03-28 2017-02-28 2017-02-03 0.7 Dividend income
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX